Document:

EX-10.1

 Exhibit 10.1 

Community Health Systems, Inc. 

2009 STOCK OPTION AND AWARD PLAN 

(As Adopted March 24, 2009 and Amended and Restated March 18, 2011, March 20, 2013, March 19, 2014 and
March 16, 2016) 
  

	1.	Purpose. 

 The purpose of this Plan is to strengthen Community Health Systems, Inc., a Delaware
corporation (the “Company”), and its Subsidiaries by providing a retention tool and an incentive to its and their employees, officers, consultants and directors, and thereby encouraging them to devote their abilities and industry to the
success of the Company’s and its Subsidiaries’ business enterprises. It is intended that this purpose be achieved by extending to employees (including future employees who have received a formal written offer of employment), officers,
consultants and directors of the Company and its Subsidiaries an added long-term incentive for high levels of performance and unusual efforts through the grant of Incentive Stock Options, Non-qualified Stock Options, Stock Appreciation Rights,
Performance Units, Performance Shares, Share Awards, Restricted Stock and Restricted Stock Units (as each term is herein defined). 
  

	2.	Definitions. 

 For purposes of the Plan: 

2.1 “2000 Stock Option and Award Plan” means the Community Health Systems, Inc. 2000 Stock Option and Award Plan, as amended and
restated March 20, 2013. 
 2.2 “Affiliate” means any entity, directly or indirectly, controlled by, controlling or under
common control with the Company or any corporation or other entity acquiring, directly or indirectly, all or substantially all the assets and business of the Company, whether by operation of law or otherwise. 

2.3 “Agreement” means the written agreement between the Company and an Optionee or Grantee evidencing the grant of an Option or
Award and setting forth the terms and conditions thereof. 
 2.4 “Award” means a grant of an Option, Restricted Stock, a
Restricted Stock Unit, a Stock Appreciation Right, a Performance Award, a Share Award or any or all of them. 
 2.5 “Board” means
the Board of Directors of the Company. 
 2.6 “Cause” means, except as otherwise set forth herein or in an applicable Agreement,

 (a) in the case of an Optionee or Grantee whose employment with the Company or a Subsidiary is subject to the terms of an employment
agreement between such Optionee or Grantee and the Company or Subsidiary, which employment agreement includes a definition of “Cause”, the term “Cause” as used in this Plan or any Agreement shall have the meaning set forth in
such employment agreement during the period that such employment agreement remains in effect; and 

 (b) in all other cases, (i) intentional failure to perform reasonably assigned duties,
(ii) dishonesty or willful misconduct in the performance of duties, (iii) involvement in a transaction in connection with the performance of duties to the Company or any of its Subsidiaries which transaction is adverse to the interests of
the Company or any of its Subsidiaries and which is engaged in for personal profit or (iv) willful violation of any law, rule or regulation in connection with the performance of duties (other than traffic violations or similar offenses);
provided, however, that following a Change in Control clause (i) of this Section 2.6(b) shall not constitute “Cause.” 

2.7 “Change in Capitalization” means any increase or reduction in the number of Shares, or any change (including, but not limited
to, in the case of a spin-off, dividend or other distribution in respect of Shares, a change in value) in the Shares or exchange of Shares for a different number or kind of shares or other securities of the Company or another corporation, by reason
of a reclassification, recapitalization, merger, consolidation, reorganization, spin-off, split-up, issuance of warrants or rights or debentures, stock dividend, stock split or reverse stock split, cash dividend, property dividend, extraordinary
cash dividend, combination or exchange of shares, repurchase of shares, change in corporate structure or otherwise. 
 2.8 A “Change in
Control” shall mean the occurrence of any of the following, unless otherwise determined by the Committee in the applicable Agreement or other written agreement approved by the Committee: 

(a) An acquisition (other than directly from the Company) of any voting securities of the Company (the “Voting Securities”) by any
“Person” (as the term person is used for purposes of Section 13(d) or 14(d) of the Exchange Act), immediately after which such Person has “Beneficial Ownership” (within the meaning of Rule 13d-3 promulgated under the
Exchange Act) of more than fifty percent (50%) of the then outstanding Shares or the combined voting power of the Company’s then outstanding Voting Securities; provided, however, that in determining whether a Change in
Control has occurred pursuant to this Section 2.8(a), Shares or Voting Securities which are acquired in a “Non-Control Acquisition” (as hereinafter defined) shall not constitute an acquisition which would cause a Change in Control. A
“Non-Control Acquisition” shall mean an acquisition by (i) an employee benefit plan (or a trust forming a part thereof) maintained by (A) the Company or (B) any corporation or other Person the majority of the voting power,
voting equity securities or equity interest of which is owned, directly or indirectly, by the Company (for purposes of this definition, a “Related Entity”), (ii) the Company or any Related Entity, or (iii) any Person in
connection with a “Non-Control Transaction” (as hereinafter defined); 
 (b) The individuals who, as of the Restatement Effective
Date, are members of the Board (the “Incumbent Board”), cease for any reason to constitute at least a majority of the members of the Board or, following a Merger (as hereinafter defined) which results in a Parent Corporation (as
hereinafter defined), the board of directors of the ultimate Parent Corporation; provided, however, that if the election, or nomination for election by the Company’s common stockholders, of any new director was approved by a vote of at least
two-thirds of the Incumbent Board, such new director shall, for purposes of this Plan, be considered a member of the Incumbent Board; provided further, however, that no individual shall be considered a member of the Incumbent Board if such
individual initially assumed office as a result of the actual or threatened solicitation of proxies or consents by or on behalf of a Person other than the Board (a “Proxy Contest”) including by reason of any agreement intended to avoid or
settle any Proxy Contest; or 

  
 2 

 (c) The consummation of: 

(i) A merger, consolidation or reorganization with or into the Company or in which securities of the Company are issued (a
“Merger”), unless such Merger is a “Non-Control Transaction.” A “Non-Control Transaction” shall mean a Merger where: 

(A) the stockholders of the Company immediately before such Merger own directly or indirectly immediately following such Merger
at least fifty percent (50%) of the combined voting power of the outstanding voting securities of (x) the corporation resulting from such Merger (the “Surviving Corporation”), if fifty percent (50%) or more of the combined
voting power of the then outstanding voting securities of the Surviving Corporation is not Beneficially Owned, directly or indirectly, by another Person (a “Parent Corporation”), or (y) if there is one or more than one Parent
Corporation, the ultimate Parent Corporation; and 
 (B) the individuals who were members of the Incumbent Board immediately
prior to the execution of the agreement providing for such Merger constitute at least a majority of the members of the board of directors of (x) the Surviving Corporation, if there is no Parent Corporation, or (y) if there is one or more
than one Parent Corporation, the ultimate Parent Corporation; 
 (ii) A complete liquidation or dissolution of the Company;
or 
 (iii) The sale or other disposition of all or substantially all of the assets of the Company to any Person (other than
a transfer to a Related Entity or under conditions that would constitute a Non-Control Transaction with the disposition of assets being regarded as a Merger for this purpose or the distribution to the Company’s stockholders of the stock of a
Related Entity or any other assets). 
 Notwithstanding the foregoing, (A) a Change in Control shall not be deemed to occur solely
because any Person (the “Subject Person”) acquired Beneficial Ownership of more than the permitted amount of the then outstanding Shares or Voting Securities as a result of the acquisition of Shares or Voting Securities by the Company
which, by reducing the number of Shares or Voting Securities then outstanding, increases the proportional number of shares Beneficially Owned by the Subject Persons, provided that if a Change in Control would occur (but for the operation of this
sentence) as a result of the acquisition of Shares or Voting Securities by the Company, and after such share acquisition by the Company, the Subject Person becomes the Beneficial Owner of any additional Shares or Voting Securities which increases
the percentage of the then outstanding Shares or Voting Securities Beneficially Owned by the Subject Person, then a Change in Control shall occur; and (B) unless otherwise provided in the applicable Agreement, with respect to any Award
constituting a “deferral of compensation” subject to Section 409A of the Code, solely for purposes of determining the timing of a payment pursuant to the Agreement, a Change in Control shall mean a “change in the ownership”
of the Company, a “change in the effective control” of the Company, or a “change in the ownership of a substantial portion of the assets” of the Company as such terms are defined in Section 1.409A-3(i)(5) of the Treasury
Regulations. 
 If an Optionee’s or Grantee’s employment is terminated by the Company without Cause prior to the date of a Change
in Control but the Optionee or Grantee reasonably demonstrates that the termination (A) was at the request of a third party who has indicated an intention or 

  
 3 

 
taken steps reasonably calculated to effect a Change in Control or (B) otherwise arose in connection with, or in anticipation of, a Change in Control which has been threatened or proposed,
such termination shall be deemed to have occurred after a Change in Control for purposes of this Plan provided a Change in Control shall actually have occurred. 

2.9 “Code” means the Internal Revenue Code of 1986, as amended. 

2.10 “Committee” means a committee, as described in Section 3.1, appointed by the Board from time to time to administer the
Plan and to perform the functions set forth herein. 
 2.11 “Company” means Community Health Systems, Inc. 

2.12 “Director” means a director of the Company. 

2.13 “Disability” means, unless otherwise defined in an Agreement: 

(a) in the case of an Optionee or Grantee whose employment with the Company or a Subsidiary is subject to the terms of an employment agreement
between such Optionee or Grantee and the Company or Subsidiary, which employment agreement includes a definition of “Disability”, the term “Disability” as used in this Plan or any Agreement shall have the meaning set forth in
such employment agreement during the period that such employment agreement remains in effect; 
 (b) in the case of an Optionee or Grantee
to whom Section 2.13(a) does not apply and who participates in the Company’s long-term disability plan, if any, the term “Disability” as used in such plan; or 

(c) in all other cases, a physical or mental infirmity which impairs the Optionee’s or Grantee’s ability to perform substantially
all his or her duties for a period of ninety-one (91) consecutive days. 
 2.14 “Division” means any of the operating units
or divisions of the Company designated as a Division by the Committee. 
 2.15 “Dividend Equivalent Right” means a right to
receive all or some portion of the cash dividends that are or would be payable with respect to Shares; provided, that subject to Section 12, no Dividend Equivalent Rights shall be granted with respect to unexercised Options or Stock
Appreciation Rights. 
 2.16 “Eligible Individual” means any of the following individuals who is designated by the Committee as
eligible to receive Options or Awards subject to the conditions set forth herein: (a) any Director or Employee, (b) any individual to whom the Company or a Subsidiary has extended a formal, written offer of employment, or (c) any
consultant or advisor of the Company or a Subsidiary. 
 2.17 “Employee” means any person, including an officer (whether or not
also a director) in the regular full-time employment of the Company or any of its Subsidiaries, but excludes, in the case of an Incentive Stock Option, an employee of any Subsidiary that is not a “subsidiary corporation” of the Company as
defined in Code Section 424(f). 
 2.18 “Exchange Act” means the Securities Exchange Act of 1934, as amended. 

  
 4 

 2.19 “Fair Market Value” on any date, unless otherwise determined by the Committee,
means the closing sales prices of the Shares on such date on the principal national securities exchange on which such Shares are listed or admitted to trading, or, if such Shares are not so listed or admitted to trading, the closing sales prices of
the Shares as reported by the Nasdaq Stock Market at the close of the primary trading session on such dates and, in either case, if the Shares were not traded on such date, on the next preceding day on which the Shares were traded. In the event that
Fair Market Value cannot be determined in a manner described above, the Fair Market Value shall be the value established by the Board in good faith. 

2.20 For purposes of this Plan, 

(a) “Good Reason” shall mean, unless otherwise provided in an Agreement, the occurrence after a Change in Control of any of the
following events or conditions: 
 (i) a change in the Optionee’s or Grantee’s status, title, position or
responsibilities (including reporting responsibilities) which, in the Optionee’s or Grantee’s reasonable judgment, represents an adverse change from the Optionee’s or Grantee’s status, title, position or responsibilities as in
effect immediately prior thereto; the assignment to the Optionee or Grantee of any duties or responsibilities which, in the Optionee’s or Grantee’s reasonable judgment, are inconsistent with the Optionee’s or Grantee’s status,
title, position or responsibilities; or any removal of the Optionee or Grantee from or failure to reappoint or reelect the Optionee or Grantee to any of such offices or positions, except in connection with the termination of the Optionee’s or
Grantee’s employment for Disability, Cause, as a result of the Optionee’s or Grantee’s death or by the Optionee or Grantee other than for Good Reason; 

(ii) a reduction in the Optionee’s or Grantee’s annual base salary below the amount as in effect immediately prior to
the Change in Control; 
 (iii) the relocation of the offices of the Optionee’s or Grantee’s place of employment to
a location more than twenty-five (25) miles from the location of such employment immediately prior to such Change in Control, or requiring the Grantee to be based anywhere other than such offices, except to the extent the Grantee was not
previously assigned to a principal location and except for required travel on business to the extent substantially consistent with the Optionee’s or Grantee’s business travel obligations at the time of the Change in Control; 

(iv) the failure to pay to the Optionee or Grantee any portion of the Optionee’s or Grantee’s current compensation or
to pay to the Optionee or Grantee any portion of an installment of deferred compensation under any deferred compensation program of the Company or any of its Subsidiaries in which the Optionee or Grantee participated, within seven (7) days of
the date such compensation is due; 
 (v) the failure to (A) continue in effect (without reduction in benefit level,
and/or reward opportunities) any material compensation or employee benefit plan in which the Optionee or Grantee was participating immediately prior to the Change in Control, unless a substitute or replacement plan has been implemented which
provides substantially identical compensation or benefits to the Optionee or Grantee or (B) provide the Optionee or Grantee with compensation and benefits, in the aggregate, at least equal (in terms of benefit levels and/or reward
opportunities) to those provided for under each other compensation or employee benefit plan, program and practice in which the Optionee or Grantee was participating immediately prior to the Change in Control; or 

  
 5 

 (vi) the failure of the Company to obtain from its successors or assigns the
express assumption and agreements required under Section 13 hereof. 
 (b) Any event or condition described in Section 2.20(a)(i),
(ii), (iii), (iv), or (vi) which occurs at any time prior to the date of a Change in Control and (1) which occurred after the Company entered into a definitive agreement, the consummation of which would constitute a Change in Control or
(2) which the Optionee or Grantee reasonably demonstrates was at the request of a third party who has indicated an intention or has taken steps reasonably calculated to effect a Change in Control, shall constitute Good Reason for purposes of
this Agreement, notwithstanding that it occurred prior to a Change in Control. 
 2.21 “Grantee” means a person to whom an Award
has been granted under the Plan. 
 2.22 “Grant Price” means the price established at the time of a grant of a Stock Appreciation
Right used to determine whether there is any payment due upon exercise of the Stock Appreciation Right. 
 2.23 “Incentive Stock
Option” means an Option satisfying the requirements of Section 422 of the Code and designated by the Committee as an Incentive Stock Option. 

2.24 “Non-Employee Director” means a Director who is not an employee of the Company. 

2.25 “Non-qualified Stock Option” means an Option which is not an Incentive Stock Option. 

2.26 “Option” means a Non-qualified Stock Option, an Incentive Stock Option or either or both of them. 

2.27 “Optionee” means a person to whom an Option has been granted under the Plan. 

2.28 “Outside Director” means a director of the Company who is an “outside director” within the meaning of
Section 162(m) of the Code and the regulations promulgated thereunder. 
 2.29 “Parent” means any corporation which is a
parent corporation within the meaning of Section 424(e) of the Code with respect to the Company. 
 2.30 “Performance Awards”
means Performance Units, Performance Shares or either or both of them. 
 2.31 “Performance-Based Compensation” means any Option
or Award that is intended to constitute “qualified performance based compensation” within the meaning of Section 162(m)(4)(C) of the Code and the regulations promulgated thereunder. 

2.32 “Performance Cycle” means the time period specified by the Committee at the time Performance Awards are granted during which
the performance of the Company, a Subsidiary or a Division will be measured. 

  
 6 

 2.33 “Performance Objectives” has the meaning set forth in Section 9. 

2.34 “Performance Shares” means Shares issued or transferred to an Eligible Individual under Section 9. 

2.35 “Performance Units” means performance units granted to an Eligible Individual under Section 9. 

2.36 “Plan” means Community Health Systems, Inc. 2009 Stock Option and Award Plan, as amended and restated from time to time. 

2.37 “Restricted Stock” means Shares issued or transferred to an Eligible Individual pursuant to Section 8.1. 

2.38 “Restricted Stock Unit” means rights granted to an Eligible Individual under Section 8.2 representing a number of
hypothetical Shares. 
 2.39 “Share Award” means an Award of Shares granted pursuant to Section 10. 

2.40 “Shares” means shares of the Common Stock of the Company, par value $.01 per share, and any other securities into which such
shares are changed or for which such shares are exchanged. 
 2.41 “Stock Appreciation Right” means a right to receive all or some
portion of the increase in the value of the Shares as provided in Section 7 hereof. 
 2.42 “Subsidiary” means
(i) except as provided in subsection (ii) below, any corporation which is a subsidiary corporation within the meaning of Section 424(f) of the Code with respect to the Company, and (ii) in relation to the eligibility to receive
Options or Awards other than Incentive Stock Options and continued employment for purposes of Options and Awards (unless the Committee determines otherwise), any entity, whether or not incorporated, in which the Company directly or indirectly owns
50% or more of the outstanding equity or other ownership interests. 
 2.43 “Successor Corporation” means a corporation, or a
Parent or Subsidiary thereof within the meaning of Section 424(a) of the Code, which issues or assumes a stock option in a transaction to which Section 424(a) of the Code applies. 

2.44 “Ten-Percent Stockholder” means an Eligible Individual, who, at the time an Incentive Stock Option is to be granted to him or
her, owns (within the meaning of Section 422(b)(6) of the Code) stock possessing more than ten percent (10%) of the total combined voting power of all classes of stock of the Company, a Parent or a Subsidiary. 

 

	3.	Administration. 

 3.1 The Plan shall be administered by the Committee, which shall hold meetings
at such times as may be necessary for the proper administration of the Plan. The Committee shall keep minutes of its meetings. If the Committee consists of more than one (1) member, a quorum shall consist of not fewer than two (2) members
of the Committee and a majority of a quorum may authorize any action. Any decision or determination reduced to writing and signed by a majority of all of the members of the Committee shall be as fully effective as if made by a

  
 7 

 
majority vote at a meeting duly called and held. The Committee shall consist of at least one (1) Director and may consist of the entire Board; provided, however, that (A) with respect
to any Option or Award granted to an Eligible Individual who is subject to Section 16 of the Exchange Act, the Committee shall consist of at least two (2) Directors each of whom shall be a “non-employee director” within the
meaning of Rule 16b-3 promulgated under the Exchange Act and (B) to the extent necessary for any Option or Award intended to qualify as Performance-Based Compensation to so qualify, the Committee shall consist of at least two
(2) Directors, each of whom shall be an Outside Director. For purposes of the preceding sentence, if any member of the Committee fails to qualify as either a non-employee director (within the meaning of subsection (A) above) or an Outside
Director, but recuses himself or herself or abstains from voting with respect to a particular action taken by the Committee, then the Committee, with respect to that action, shall be deemed to consist only of the members of the Committee who have
not recused themselves or abstained from voting. Subject to applicable law, the Committee may delegate its authority under the Plan to any other person or persons. 

3.2 No member of the Committee shall be liable for any action, failure to act, determination or interpretation made in good faith with respect
to this Plan or any transaction hereunder. The Company hereby agrees to indemnify each member of the Committee for all costs and expenses and, to the extent permitted by applicable law, any liability incurred in connection with defending against,
responding to, negotiating for the settlement of or otherwise dealing with any claim, cause of action or dispute of any kind arising in connection with any actions in administering this Plan or in authorizing or denying authorization to any
transaction hereunder. 
 3.3 Subject to the express terms and conditions set forth herein, the Committee shall have the power from time to
time to: 
 (a) determine those Eligible Individuals to whom Options shall be granted under the Plan and the number of such Options to be
granted, prescribe the terms and conditions (which need not be identical) of each such Option, including the exercise price per Share, the vesting schedule and the duration of each Option, and make any amendment or modification to any Option
Agreement consistent with the terms of the Plan; 
 (b) select those Eligible Individuals to whom Awards shall be granted under the Plan,
determine the number of Shares in respect of which each Award is granted, the terms and conditions (which need not be identical) of each such Award, and make any amendment or modification to any Award Agreement consistent with the terms of the Plan;

 (c) construe and interpret the Plan and the Options and Awards granted hereunder, establish, amend and revoke rules and regulations for
the administration of the Plan, including, but not limited to, correcting any defect or supplying any omission, or reconciling any inconsistency in the Plan or in any Agreement, in the manner and to the extent it shall deem necessary or advisable,
including so that the Plan and the operation of the Plan comply with Rule 16b-3 under the Exchange Act, the Code to the extent applicable and other applicable law, and otherwise make the Plan fully effective. All decisions and determinations by the
Committee in the exercise of this power shall be final, binding and conclusive upon the Company, its Subsidiaries, the Optionees and Grantees, and all other persons having any interest therein; 

(d) determine the duration and purposes for leaves of absence which may be granted to an Optionee or Grantee on an individual basis without
constituting a termination of employment or service for purposes of the Plan; 

  
 8 

 (e) exercise its discretion with respect to the powers and rights granted to it as set forth in
the Plan; and 
 (f) generally, exercise such powers and perform such acts as are deemed necessary or advisable to promote the best
interests of the Company with respect to the Plan. 
 3.4 The Committee may delegate to one or more officers of the Company the authority to
grant Options or Awards to Eligible Individuals (other than to himself or herself) and/or determine the number of Shares subject to each Option or Award (by resolution that specifies the total number of Shares subject to the Options or Awards that
may be awarded by the officer and the terms of any such Options or Awards, including the exercise price), provided that such delegation is made in accordance with the Delaware General Corporation Law and with respect to Options and Awards that are
not intended to qualify as Performance-Based Compensation and that are not made to executive officers of the Company covered by Rule 16b-3 under the Exchange Act. 
  

	4.	Shares Subject to the Plan; Grant Limitations. 

 4.1 Shares Subject to the Plan.
The maximum number of Shares that may be made the subject of Options and Awards granted under the Plan is the sum of: 
 (a) 5,000,000
Shares added to the Plan as a result of the amendment and restatement effective on the Restatement Effective Date; and 
 (b) 1,114,842
Shares remaining in the Plan as of March 16, 2016; 
 (c) for a total of 6,114,842 Shares, less any Shares subject to Options or Awards
granted after March 16, 2016. 
 The Company shall reserve for the purposes of the Plan, out of its authorized but unissued Shares or
out of Shares held in the Company’s treasury, or partly out of each, such number of Shares as shall be determined by the Board. No further grants may be made under the 2000 Stock Option and Award Plan, but Options and Awards made under the 2000
Stock Option and Award Plan shall remain outstanding in accordance with their terms. 
 4.2 Shares Returned to the Plan. Whenever any
outstanding Option or Award or portion thereof granted pursuant to the 2000 Stock Option and Award Plan and outstanding as of March 16, 2016 would have again been available for grant as an Option or Award pursuant to Section 4.3 of the
2000 Stock Option and Award Plan as in effect on March 20, 2013, the number of Shares allocable to the expired, canceled, forfeited, settled or otherwise terminated portion of such Option or Award, determined in accordance with Section 4.3
of the 2000 Stock Option and Award Plan, shall be added to the maximum number of Shares available to be granted as Options or Awards granted hereunder. 

4.3 Grant Limitations. The following grant limitations shall apply when making Awards pursuant to the Plan: 

(a) No Eligible Individual (other than a Non-Employee Director) may be granted Options in respect of more than 1,000,000 Shares, or Options or
Awards in the aggregate in respect of more than 1,000,000 Shares, in any calendar year; 

  
 9 

 (b) No Non-Employee Director may be granted Options in respect of more than 100,000 Shares in any
calendar year, or Options or Awards in the aggregate in respect of more than 100,000 Shares in any calendar year, and the maximum grant date fair value of all Awards granted during any calendar year to a single Non-Employee Director shall not exceed
$1,000,000; 
 (c) In no event shall more than an aggregate of 30,000 Shares be issued upon the exercise of Incentive Stock Options granted
under the Plan. 
 4.4 Fungible Plan Design. Upon the granting of an Option or an Award, the number of Shares available under
Section 4.1 for the granting of further Options and Awards shall be reduced as follows: 
 (a) In connection with the granting of an
Option or an Award, the number of Shares shall be reduced by the number of Shares in respect of which the Option or Award is granted or denominated. 

(b) Stock Appreciation Rights to be settled in Shares shall be counted in full against the number of Shares available for award under the
Plan, regardless of the number of Shares issued upon settlement of the Stock Appreciation Right. 
 (c) Notwithstanding the foregoing,
Awards granted in the form of Restricted Stock (including Restricted Stock Units), Share-settled Performance Awards and other Awards that are granted as “full value awards” shall reduce the number of Shares that may be the subject to
Options and Awards under the Plan by 1.52 Shares for each Share subject to such an Award. 
 4.5 Whenever any outstanding Option or Award or
portion thereof expires, is canceled, is forfeited, is settled in cash or is otherwise terminated for any reason without having been exercised or Shares having been issued in respect of the Option or Award (or such portion thereof to which the
expiration, forfeiture, cash settlement or other termination occurs), the Shares allocable to the expired, canceled, forfeited, cash-settled or otherwise terminated portion of the Option or Award may again be the subject of Options or Awards granted
hereunder. With regard to Awards referred to in Section 4.4(c), for each Share subject to an Award that is cancelled, forfeited, settled in cash or other otherwise terminated as provided in the foregoing sentence, 1.52 Shares may again be the
subject of Options or Awards under the Plan. Notwithstanding the foregoing, the following events shall not result in any increase in Shares available for issuance of Options or Awards under the Plan or such Shares again becoming available for
issuance of Options or Awards: 
 (a) Withholding of Shares to pay Taxes on any Option or Award, 

(b) The excess of the number of Shares subject to any stock-settled Stock Appreciation Rights over the number of Shares actually issued in
settlement thereof, 
 (c) Tendering of Shares to pay for Option exercise prices or Withholding Taxes (i.e., net settlement of Shares), and

 (d) The purchase of Shares on the open market as a result of Option exercises. 

  
 10 

 4.6 Unless otherwise determined by the Committee, in no event shall an Option or Award to a
Participant other than a Non-Employee Director not subject to performance-based conditions have a vesting schedule resulting in such Option or Award vesting in full prior to the third anniversary of the grant date. For purposes of clarity, this
restriction will not prohibit any Option or Award from having partial vesting dates prior to the third anniversary of the grant date in accordance with a proportionate vesting schedule determined at the discretion of the Committee, so long as such
Option or Award does not vest in full prior to the third anniversary of the grant date. 
  

	5.	Option Grants for Eligible Individuals. 

 5.1 Authority of Committee. Subject to the
provisions of the Plan, the Committee shall have full and final authority to select those Eligible Individuals who will receive Options, and the terms and conditions of the grant to such Eligible Individuals shall be set forth in an Agreement.
Incentive Stock Options may be granted only to Eligible Individuals who are employees of the Company or any Subsidiary. 
 5.2 Exercise
Price. The purchase price or the manner in which the exercise price is to be determined for Shares under each Option shall be determined by the Committee and set forth in the Agreement; provided, however, that the exercise price
per Share under each Non-qualified Stock Option and each Incentive Stock Option shall not be less than 100% of the Fair Market Value of a Share on the date the Option is granted (110% in the case of an Incentive Stock Option granted to a Ten-Percent
Stockholder). 
 5.3 Maximum Duration. Options granted hereunder shall be for such term as the Committee shall determine, provided
that an Incentive Stock Option shall not be exercisable after the expiration of ten (10) years from the date it is granted (five (5) years in the case of an Incentive Stock Option granted to a Ten-Percent Stockholder) and a Non-qualified
Stock Option shall not be exercisable after the expiration of ten (10) years from the date it is granted; provided, however, that unless the Committee provides otherwise, an Option (other than an Incentive Stock Option) may, upon the death of
the Optionee prior to the expiration of the Option, be exercised for up to one (1) year following the date of the Optionee’s death even if such period extends beyond ten (10) years from the date the Option is granted. The Committee
may, subsequent to the granting of any Option, extend the term thereof, but in no event shall the term as so extended exceed the maximum term provided for in the preceding sentence. 

5.4 Vesting. Subject to Section 5.10, each Option shall become exercisable in such installments (which need not be equal) and at
such times as may be designated by the Committee and set forth in the Agreement. To the extent not exercised, installments shall accumulate and be exercisable, in whole or in part, at any time after becoming exercisable, but not later than the date
the Option expires. The Committee may accelerate the exercisability of any Option or portion thereof at any time. 
 5.5 Deferred
Delivery of Option Shares. The Committee may, in its discretion, permit Optionees to elect to defer the issuance of Shares upon the exercise of one or more Non-qualified Stock Options granted pursuant to the Plan. The terms and conditions of
such deferral shall be determined at the time of the grant of the Option or thereafter and shall be set forth in the Agreement evidencing the Option. 

5.6 Limitations on Incentive Stock Options. To the extent that the aggregate Fair Market Value (determined as of the date of the grant)
of Shares with respect to which Incentive 

  
 11 

 
Stock Options granted under the Plan and “incentive stock options” (within the meaning of Section 422 of the Code) granted under all other plans of the Company or its Subsidiaries
(in either case determined without regard to this Section 5.6) are exercisable by an Optionee for the first time during any calendar year exceeds $100,000, such Incentive Stock Options shall be treated as Non-qualified Stock Options. In
applying the limitation in the preceding sentence in the case of multiple Option grants, Options which were intended to be Incentive Stock Options shall be treated as Non-qualified Stock Options according to the order in which they were granted such
that the most recently granted Options are first treated as Non-qualified Stock Options. 
 5.7 Non-Transferability. No Option shall
be transferable by the Optionee otherwise than by will or by the laws of descent and distribution or, in the case of an Option other than an Incentive Stock Option, pursuant to a domestic relations order (within the meaning of Rule 16a-12
promulgated under the Exchange Act), and an Option shall be exercisable during the lifetime of such Optionee only by the Optionee or his or her guardian or legal representative. Notwithstanding the foregoing, the Committee may set forth in the
Agreement evidencing an Option (other than an Incentive Stock Option), at the time of grant or thereafter, that the Option may be transferred to members of the Optionee’s immediate family, to trusts solely for the benefit of such immediate
family members and to partnerships in which such family members and/or trusts are the only partners, and for purposes of this Plan, a transferee of an Option shall be deemed to be the Optionee. For this purpose, immediate family means the
Optionee’s spouse, parents, children, stepchildren and grandchildren and the spouses of such parents, children, stepchildren and grandchildren. The terms of an Option shall be final, binding and conclusive upon the beneficiaries, executors,
administrators, heirs and successors of the Optionee. 
 5.8 Method of Exercise. The exercise of an Option shall be made only by a
written notice delivered in person or by mail, or by such other means acceptable to the Committee and communicated to an Optionee, to the Secretary of the Company at the Company’s principal executive office, specifying the number of Options to
be exercised and, to the extent applicable, accompanied by payment therefor and otherwise in accordance with the Agreement pursuant to which the Option was granted; provided, however, that Options may not be exercised by an Optionee following
a hardship distribution to the Optionee to the extent such exercise is prohibited under the Community Health Systems, Inc. 401(k) Plan. The exercise price for any Shares purchased pursuant to the exercise of an Option shall be paid in either of the
following forms (or any combination thereof): (a) cash or (b) the transfer, either actually or by attestation, to the Company of Shares owned by the Optionee prior to the exercise of the Option, such transfer to be upon such terms and
conditions as determined by the Committee or (c) a combination of cash and the transfer of Shares; provided, however, that the Committee may determine that the exercise price shall be paid only in cash. In addition, Options may be
exercised through a registered broker-dealer or directly with the Company pursuant to such cashless exercise procedures which are, from time to time, deemed acceptable by the Committee. Any Shares transferred to the Company as payment of the
exercise price under an Option shall be valued at their Fair Market Value on the day of exercise of such Option. If requested by the Committee, the Optionee shall deliver the Agreement evidencing the Option to the Secretary of the Company who shall
endorse thereon a notation of such exercise and return such Agreement to the Optionee. No fractional Shares (or cash in lieu thereof) shall be issued upon exercise of an Option and the number of Shares that may be purchased upon exercise shall be
rounded to the nearest number of whole Shares. 

  
 12 

 5.9 Rights of Optionees. No Optionee shall be deemed for any purpose to be the owner of
any Shares subject to any Option unless and until (a) the Option shall have been exercised pursuant to the terms thereof, (b) the Company shall have issued and delivered Shares to the Optionee, and (c) the Optionee’s name shall
have been entered as a stockholder of record on the books of the Company or otherwise evidenced by a “book entry” (i.e., a computerized or manual entry) in the records of the Company or its designated agent. Thereupon, the Optionee
shall have full voting, dividend and other ownership rights with respect to such Shares, subject to such terms and conditions as may be set forth in the applicable Agreement. 

5.10 Effect of Change in Control. Section 13(b) shall control the treatment of any Options outstanding at the time of a Change in
Control. Except as otherwise provided by the Committee, any Options that are exercisable as of a Change in Control shall remain exercisable for a period ending not before the earlier of (x) the six (6) month anniversary of the Change in
Control or (y) the expiration of the stated term of the Option. 
  

	6.	Limitations on Repricing. 

 Notwithstanding anything in the Plan to the contrary, except as
permitted or required by the provisions of Sections 12 or 13 hereof, neither the Board nor the Committee shall have the power to (i) lower the Option Price of an Option after it is granted, (ii) lower the Grant Price of a Stock
Appreciation Right after it is granted, (iii) cancel an Option when the exercise price thereof exceeds the Fair Market Value of the underlying Shares in exchange for cash or another Award or grant substitute Options with a lower exercise price
than the cancelled Options, (iv) cancel a Stock Appreciation Right when the Grant Price exceeds the Fair Market Value of the underlying Shares in exchange for cash or another Award, or grant substitute Stock Appreciation Rights with a lower
Grant Price than the cancelled Award, or (v) take any other action with respect to an Option or Stock Appreciation Right that would be treated as a repricing under the rules and regulations of the principal securities exchange on which the
Shares are traded, in each case without the approval of the Company’s stockholders. 
  

	7.	Stock Appreciation Rights. 

 The Committee may in its discretion, either alone or in connection
with the grant of an Option, grant Stock Appreciation Rights in accordance with the Plan, the terms and conditions of which shall be set forth in an Agreement. If granted in connection with an Option, a Stock Appreciation Right shall cover the same
Shares covered by the Option (or such lesser number of Shares as the Committee may determine) and shall, except as provided in this Section 7, be subject to the same terms and conditions as the related Option. 

7.1 Time of Grant. A Stock Appreciation Right may be granted (a) at any time if unrelated to an Option, or (b) if related to
an Option, either at the time of grant or at any time thereafter during the term of the Option. 
 7.2 Stock Appreciation Right Related
to an Option. 
 (a) Exercise. A Stock Appreciation Right granted in connection with an Option shall be exercisable at such time
or times and only to the extent that the related Option is exercisable, and will not be transferable except to the extent the related Option may be transferable. A Stock Appreciation Right granted in connection with an Incentive Stock Option shall
be exercisable only if the Fair Market Value of a Share on the date of exercise exceeds the exercise price specified in the related Incentive Stock Option Agreement. In no event shall a Stock Appreciation Right related to an Option have a term of
greater than ten (10) years. 

  
 13 

 (b) Amount Payable. Upon the exercise of a Stock Appreciation Right related to an Option,
the Grantee shall be entitled to receive an amount determined by multiplying (i) the excess of the Fair Market Value of a Share on the date of exercise of such Stock Appreciation Right over the per Share exercise price under the related Option,
by (ii) the number of Shares as to which such Stock Appreciation Right is being exercised. Notwithstanding the foregoing, the Committee may limit in any manner the amount payable with respect to any Stock Appreciation Right by including such a
limit in the Agreement evidencing the Stock Appreciation Right at the time it is granted. 
 (c) Treatment of Related Options and Stock
Appreciation Rights Upon Exercise. Upon the exercise of a Stock Appreciation Right granted in connection with an Option, the Option shall be canceled to the extent of the number of Shares as to which the Stock Appreciation Right is exercised,
and upon the exercise of an Option granted in connection with a Stock Appreciation Right, the Stock Appreciation Right shall be canceled to the extent of the number of Shares as to which the Option is exercised or surrendered. 

7.3 Stock Appreciation Right Unrelated to an Option. The Committee may grant to Eligible Individuals Stock Appreciation Rights
unrelated to Options. Stock Appreciation Rights unrelated to Options shall contain such terms and conditions as to exercisability (subject to Section 7.7), vesting and duration as the Committee shall determine, but in no event shall they have a
term of greater than ten (10) years. The Committee shall establish the Grant Price at the time each Stock Appreciation Right unrelated to an Option is granted, which shall not be less than the Fair Market Value of a Share on the date the Stock
Appreciation Right is granted. Upon exercise of a Stock Appreciation Right unrelated to an Option, the Grantee shall be entitled to receive an amount determined by multiplying (a) the excess of the Fair Market Value of a Share on the date of
exercise of such Stock Appreciation Right over the Grant Price of the Stock Appreciation Right, by (b) the number of Shares as to which the Stock Appreciation Right is being exercised. Notwithstanding the foregoing, the Committee may limit in
any manner the amount payable with respect to any Stock Appreciation Right by including such a limit in the Agreement evidencing the Stock Appreciation Right at the time it is granted. 

7.4 Non-Transferability. No Stock Appreciation Right shall be transferable by the Grantee otherwise than by will or by the laws of
descent and distribution or pursuant to a domestic relations order (within the meaning of Rule 16a-12 promulgated under the Exchange Act), and such Stock Appreciation Right shall be exercisable during the lifetime of such Grantee only by the Grantee
or his or her guardian or legal representative. The terms of such Stock Appreciation Right shall be final, binding and conclusive upon the beneficiaries, executors, administrators, heirs and successors of the Grantee. 

7.5 Method of Exercise. Stock Appreciation Rights shall be exercised by a Grantee only by a written notice delivered in person or by
mail, or by such other means acceptable to the Committee and communicated to the Grantee, to the Secretary of the Company at the Company’s principal executive office, specifying the number of Shares with respect to which the Stock Appreciation
Right is being exercised. If requested by the Committee, the Grantee shall deliver the Agreement evidencing the Stock Appreciation Right being exercised and the Agreement evidencing any related Option to the Secretary of the Company who shall
endorse thereon a notation of such exercise and return such Agreement to the Grantee. 

  
 14 

 7.6 Form of Payment. Payment of the amount determined under Sections 7.2(b) or 7.3 may be
made in the discretion of the Committee solely in whole Shares in a number determined at their Fair Market Value on the date of exercise of the Stock Appreciation Right, or solely in cash, or in a combination of cash and Shares. If the Committee
decides to make full payment in Shares and the amount payable results in a fractional Share, payment for the fractional Share will be made in cash. 

7.7 Effect of Change in Control. Section 13(b) shall control the treatment of any Stock Appreciation Rights outstanding at the
time of a Change in Control. Except as otherwise provided by the Committee, any Stock Appreciation Rights that are exercisable as of a Change in Control shall remain exercisable for a period ending not before the earlier of (x) the six
(6) month anniversary of the Change in Control or (y) the expiration of the stated term of the Stock Appreciation Right. 
  

	8.	Restricted Stock and Restricted Stock Units. 

 8.1 Restricted Stock. The Committee may
grant Awards to Eligible Individuals of Restricted Stock, which shall be evidenced by an Agreement between the Company and the Grantee. Each Agreement shall contain such restrictions, terms and conditions as the Committee may, in its discretion,
determine and (without limiting the generality of the foregoing) such Agreements may require that an appropriate legend be placed on Share certificates. The Committee may, in its discretion, provide that a Participant’s ownership of Restricted
Stock prior to the lapse of any transfer restrictions or any other applicable restrictions shall, in lieu of such certificates, be evidenced by a “book entry” (i.e., a computerized or manual entry) in the records of the Company or
its designated agent in the name of the Participant who has received such Award, and confirmation and account statements sent to the Participant with respect to such book entry Shares may bear the restrictive legend referenced in the preceding
sentence. Such records of the Company or such agent shall, absent manifest error, be binding on all Participants who receive Restricted Stock Awards evidenced in such manner. Awards of Restricted Stock shall be subject to the terms and provisions
set forth below in this Section 8.1. 
 (a) Rights of Grantee. Subject to the foregoing provisions concerning book entry
issuance, Shares of Restricted Stock granted pursuant to an Award hereunder shall be issued in the name of the Grantee as soon as reasonably practicable after the Award is granted provided that the Grantee has executed an Agreement evidencing the
Award, the appropriate blank stock powers and, in the discretion of the Committee, an escrow agreement and any other documents which the Committee may require as a condition to the issuance of such Shares. If a Grantee shall fail to execute the
Agreement evidencing a Restricted Stock Award, or any documents which the Committee may require within the time period prescribed by the Committee at the time the Award is granted, the Award shall be null and void. At the discretion of the
Committee, Shares issued in connection with a Restricted Stock Award shall be deposited together with the stock powers with an escrow agent (which may be the Company) designated by the Committee. Unless the Committee determines otherwise and as set
forth in the Agreement, upon delivery of the Shares to the escrow agent, the Grantee shall have all of the rights of a stockholder with respect to such Shares, including the right to vote the Shares and to receive all dividends or other
distributions paid or made with respect to the Shares. 
 (b) Non-Transferability. Until all restrictions upon the Shares of
Restricted Stock awarded to a Grantee shall have lapsed in the manner set forth in Section 8.1(c), such Shares shall not be sold, transferred or otherwise disposed of and shall not be pledged or otherwise hypothecated. 

  
 15 

 (c) Lapse of Restrictions. 

(i) Generally. Restrictions upon Shares of Restricted Stock awarded hereunder shall lapse at such time or times and on
such terms and conditions as the Committee may determine. The Agreement evidencing the Award shall set forth any such restrictions. 

(ii) Effect of Change in Control. Section 13(b) shall control the treatment of any Shares of Restricted Stock then
outstanding in the event of a Change in Control. 
 (d) Treatment of Dividends. At the time an Award of Shares of Restricted Stock is
granted, the Committee may, in its discretion, determine that the payment to the Grantee of dividends, or a specified portion thereof, declared or paid on such Shares by the Company shall be (a) deferred until the lapsing of the restrictions
imposed upon such Shares and (b) held by the Company for the account of the Grantee until such time. In the event that dividends are to be deferred, the Committee shall determine whether such dividends are to be reinvested in Shares (which
shall be held as additional Shares of Restricted Stock) or held in cash. If deferred dividends are to be held in cash, there may be credited at the end of each year (or portion thereof) interest on the amount of the account at the beginning of the
year at a rate per annum as the Committee, in its discretion, may determine. Payment of deferred dividends in respect of Shares of Restricted Stock (whether held in cash or as additional Shares of Restricted Stock), together with interest accrued
thereon, if any, shall be made upon the lapsing of restrictions imposed on the Shares in respect of which the deferred dividends were paid, and any dividends deferred (together with any interest accrued thereon) in respect of any Shares of
Restricted Stock shall be forfeited upon the forfeiture of such Shares. 
 (e) Delivery of Shares. Upon the lapse of the restrictions
on Shares of Restricted Stock, the Committee shall cause a stock certificate to be delivered to the Grantee with respect to such Shares, free of all restrictions hereunder (or, in the case of book entry Shares, such restrictions and legend shall be
removed from the confirmation and account statements delivered to the Participant or the Participant’s beneficiary or estate, as the case may be, in book-entry form). 

8.2 Restricted Stock Units. The Committee may grant to Eligible Individuals Awards of Restricted Stock Units, which shall be evidenced
by an Agreement. Each such Agreement shall contain such restrictions, terms and conditions as the Committee may, in its discretion, determine. Awards of Restricted Stock Units shall be subject to the terms and provisions set forth below in this
Section 8.2. 
 (a) Payment of Awards. Each Restricted Stock Unit shall represent the right of a Grantee to receive a payment
upon vesting of the Restricted Stock Unit or on any later date specified by the Committee equal to the Fair Market Value of a Share as of the date the Restricted Stock Unit was granted, the vesting date or such other date as determined by the
Committee at the time the Restricted Stock Unit was granted. The Committee may, at the time a Restricted Stock Unit is granted, provide a limitation on the amount payable in respect of each Restricted Stock Unit and may provide for Dividend
Equivalent Rights with respect to such Award; provided, that no Dividend Equivalent Rights shall be paid except to the extent the underlying Restricted Stock Unit is paid or settled. The Committee may provide for the settlement of Restricted Stock
Units in cash or with Shares having a Fair Market Value equal to the payment to which the Grantee has become entitled. 

  
 16 

 (b) Effect of Change in Control. Section 13(b) shall control the treatment of any
Restricted Stock Units then outstanding in the event of a Change in Control. 
  

	9.	Performance Awards. 

 9.1 Performance Units. The Committee, in its discretion, may grant
Awards of Performance Units to Eligible Individuals, the terms and conditions of which shall be set forth in an Agreement between the Company and the Grantee; provided that, no Eligible Individual may be granted Performance Awards in the aggregate
in respect of more than 1,000,000 Shares in any calendar year. Contingent upon the attainment of specified Performance Objectives within the Performance Cycle, Performance Units represent the right to receive payment as provided in
Section 9.1(b) of (i) the Fair Market Value of a Share on the date the Performance Unit was granted, the date the Performance Unit became vested or any other date specified by the Committee or (ii) a percentage (which may be more than
100%) of the amount described in clause (i) depending on the level of Performance Objective attainment; provided, however, that the Committee may at the time a Performance Unit is granted specify a maximum amount payable in respect of a
vested Performance Unit. Each Agreement shall specify the number of Performance Units to which it relates, the Performance Objectives which must be satisfied in order for the Performance Units to vest and the Performance Cycle within which such
Performance Objectives must be satisfied. At the time a Performance Unit is granted, the Committee may provide for Dividend Equivalent Rights with respect to such Award; provided, that no Dividend Equivalent Rights shall be paid except to the extent
the underlying Performance Unit is paid or settled. 
 (a) Vesting and Forfeiture. Subject to Sections 9.3(c) and 9.4, a Grantee
shall become vested with respect to the Performance Units to the extent that the Performance Objectives set forth in the Agreement are satisfied for the Performance Cycle. 

(b) Payment of Awards. Subject to Section 9.3(c), payment to Grantees in respect of vested Performance Units shall be made as soon
as practicable after the last day of the Performance Cycle to which such Award relates unless the Agreement evidencing the Award provides for the deferral of payment, in which event the terms and conditions of the deferral shall be set forth in the
Agreement. Subject to Section 9.4, such payments may be made entirely in Shares valued at their Fair Market Value, entirely in cash, or in such combination of Shares and cash as the Committee in its discretion shall determine at any time prior
to such payment, provided, however, that if the Committee in its discretion determines to make such payment entirely or partially in Shares of Restricted Stock, the Committee must determine the extent to which such payment will be in Shares
of Restricted Stock and the terms of such Restricted Stock at the time the Award is granted. 
 9.2 Performance Shares. The
Committee, in its discretion, may grant Awards of Performance Shares to Eligible Individuals, the terms and conditions of which shall be set forth in an Agreement between the Company and the Grantee. Each Agreement may require that an appropriate
legend be placed on Share certificates. Awards of Performance Shares shall be subject to the following terms and provisions: 
 (a)
Rights of Grantee. The Committee shall provide at the time an Award of Performance Shares is made the time or times at which the actual Shares represented by such Award shall be issued in the name of the Grantee; provided, however,
that no Performance Shares shall be issued until the Grantee has executed an Agreement evidencing the Award, the appropriate blank stock powers and, in the discretion of the Committee, an escrow agreement

  
 17 

 
and any other documents which the Committee may require as a condition to the issuance of such Performance Shares. If a Grantee shall fail to execute the Agreement evidencing an Award of
Performance Shares, the appropriate blank stock powers and, in the discretion of the Committee, an escrow agreement and any other documents which the Committee may require within the time period prescribed by the Committee at the time the Award is
granted, the Award shall be null and void. At the discretion of the Committee, Shares issued in connection with an Award of Performance Shares shall be deposited together with the stock powers with an escrow agent (which may be the Company)
designated by the Committee. Alternatively, the Committee may, in its discretion, provide that Performance Shares shall be evidenced by the book entry procedures set forth in Section 8.1. Except as restricted by the terms of the Agreement, upon
delivery of the Shares to the escrow agent, or the book entry of such Shares, the Grantee shall have, in the discretion of the Committee, all of the rights of a stockholder with respect to such Shares, including the right to vote the Shares and to
receive all dividends or other distributions paid or made with respect to the Shares. 
 (b) Non-Transferability. Until any
restrictions upon the Performance Shares awarded to a Grantee shall have lapsed in the manner set forth in Section 9.2(c) or 9.4, such Performance Shares shall not be sold, transferred or otherwise disposed of and shall not be pledged or
otherwise hypothecated, nor shall they be delivered to the Grantee. The Committee may also impose such other restrictions and conditions on the Performance Shares, if any, as it deems appropriate. 

(c) Lapse of Restrictions. Subject to Sections 9.3(c) and 9.4, restrictions upon Performance Shares awarded hereunder shall lapse and
such Performance Shares shall become vested at such time or times and on such terms, conditions and satisfaction of Performance Objectives as the Committee may, in its discretion, determine at the time an Award is granted. 

(d) Treatment of Dividends. The payment to the Grantee of dividends, or a specified portion thereof, declared or paid on Shares
represented by an Award of Performance Shares which have been issued by the Company to the Grantee shall be (i) deferred until the lapsing of the restrictions imposed upon such Performance Shares and (ii) held by the Company or its agent
for the account of the Grantee until such time. The Committee shall determine whether such dividends are to be reinvested in shares of Stock (which shall be held as additional Performance Shares) or held in cash. If deferred dividends are to be held
in cash, there may be credited at the end of each year (or portion thereof) interest on the amount of the account at the beginning of the year at a rate per annum as the Committee, in its discretion, may determine. Payment of deferred dividends in
respect of Performance Shares (whether held in cash or in additional Performance Shares), together with interest accrued thereon, if any, shall be made upon the lapsing of restrictions imposed on the Performance Shares in respect of which the
deferred dividends were paid, and any dividends deferred (together with any interest accrued thereon) in respect of any Performance Shares shall be forfeited upon the forfeiture of such Performance Shares. 

(e) Delivery of Shares. Upon the lapse of the restrictions on Performance Shares awarded hereunder, the Committee shall cause a stock
certificate to be delivered to the Grantee with respect to such Shares, free of all restrictions hereunder, or in the case of book entry Shares, such restrictions and legend shall be removed from the confirmation and account statements delivered to
the Participant or the Participant’s beneficiary or estate, as the case may be. 

  
 18 

 9.3 Performance Objectives. 

(a) Establishment. Performance Objectives for Performance Awards may be expressed in terms of (i) earnings per Share, (ii) net
revenue, (iii) adjusted EBITDA (iv) Share price, (v) pre-tax profits, (vi) net earnings, (vii) return on equity or assets, (viii) operating income, (ix) EBITDA margin, (x) EBITDA margin improvement,
(xi) bad debt expense, (xii) cash receipts, (xiii) uncompensated care expense, (xiv) days in net revenue in net patient accounts receivable, (xv) gross income, (xvi) net income (before or after taxes), (xvii) cash
flow; (xviii) gross profit, (xix) gross profit return on investment, (xx) gross margin return on investment, (xxi) gross margin; (xxii) operating margin, (xxiii) working capital, (xxiv) earnings before interest and
taxes, (xxv) return on capital, (xxvi) return on invested capital, (xxvii) revenue growth, (xxviii) annual recurring revenues, (xxix) recurring revenues, (xxx) total shareholder return, (xxxi) economic value added,
(xxxii) specified objectives with regard to limiting the level of increase in all or a portion of the Company’s bank debt or other long-term or short-term public or private debt or other similar financial obligations of the Company, which
may be calculated net of cash balances and/or other offsets and adjustments as may be established by the Committee in its sole discretion, (xxxiii) reduction in operating expenses, or (xxxiv) any combination of the foregoing. Performance
Objectives may be in respect of the performance of the Company, any of its Subsidiaries, any of its Divisions or any combination thereof. Performance Objectives may be absolute or relative (to prior performance of the Company or to the performance
of one or more other entities or external indices) and may be expressed in terms of a progression within a specified range. The Performance Objectives with respect to a Performance Cycle shall be established in writing by the Committee by the
earlier of (x) the date on which a quarter of the Performance Cycle has elapsed or (y) the date which is ninety (90) days after the commencement of the Performance Cycle, and in any event while the performance relating to the
Performance Objectives remain substantially uncertain. 
 (b) Effect of Certain Events. At the time of the granting of a Performance
Award, or at any time thereafter, in either case to the extent permitted under Section 162(m) of the Code and the regulations thereunder without adversely affecting the treatment of the Performance Award as Performance-Based Compensation, the
Committee may provide for the manner in which performance will be measured against the Performance Objectives (or may adjust the Performance Objectives) to reflect the impact of specified corporate transactions, accounting or tax law changes and
other extraordinary, unusual or nonrecurring events. 
 (c) Determination of Performance. Prior to the vesting, payment, settlement
or lapsing of any restrictions with respect to any Performance Award that is intended to constitute Performance-Based Compensation made to a Grantee who is subject to Section 162(m) of the Code, the Committee shall certify in writing that the
applicable Performance Objectives have been satisfied to the extent necessary for such Award to qualify as Performance Based Compensation. 

9.4 Effect of Change in Control. Section 13(b) shall control the treatment of any Performance Units then outstanding in the event
of a Change in Control. 
 9.5 Non-Transferability. Until the vesting of Performance Units or the lapsing of any restrictions on
Performance Shares, as the case may be, such Performance Units or Performance Shares shall not be sold, transferred or otherwise disposed of and shall not be pledged or otherwise hypothecated. 

  
 19 

	10.	Share Awards. 

 The Committee may grant a Share Award to any Eligible Individual on such terms
and conditions as the Committee may determine in its sole discretion. Share Awards may be made as additional compensation for services rendered by the Eligible Individual or may be in lieu of cash or other compensation to which the Eligible
Individual is entitled from the Company. 
  

	11.	Effect of a Termination of Employment. 

 The Agreement evidencing the grant of each Option and
each Award shall set forth the terms and conditions applicable to such Option or Award upon a termination or change in the status of the employment of the Optionee or Grantee by the Company, a Subsidiary or a Division (including a termination or
change by reason of the sale of a Subsidiary or a Division), which shall be as the Committee may, in its discretion, determine at the time the Option or Award is granted or thereafter. 

 

	12.	Adjustment Upon Changes in Capitalization. 

 (a) In the event of a Change in Capitalization, the
Committee shall conclusively determine the appropriate adjustments, if any, to (i) the maximum number and class of Shares or other stock or securities with respect to which Options or Awards may be granted under the Plan, (ii) the number
and class of Shares or other stock or securities which are subject to outstanding Options or Awards granted under the Plan and the exercise price therefor, if applicable, and (iii) the Performance Objectives. 

(b) Any such adjustment in the Shares or other stock or securities (a) subject to outstanding Incentive Stock Options (including any
adjustments in the exercise price) shall be made in such manner as not to constitute a modification as defined by Section 424(h)(3) of the Code and only to the extent permitted by Sections 422 and 424 of the Code or (b) subject to
outstanding Options or Awards that are intended to qualify as Performance-Based Compensation shall be made in such a manner as not to adversely affect the treatment of the Options or Awards as Performance-Based Compensation. In addition, (a) no
adjustment to any Option or Award that is not subject to Section 409A of the Code shall be made in a manner that would subject the Option or Award to Section 409A of the Code and (b) any adjustment to an Option or Award that is
subject to Section 409A of the Code shall be made only in a manner and to the extent permitted by Section 409A of the Code. 
 (c)
If, by reason of a Change in Capitalization, a Grantee of an Award shall be entitled to, or an Optionee shall be entitled to exercise an Option with respect to, new, additional or different shares of stock or securities of the Company or any other
corporation, such new, additional or different shares shall thereupon be subject to all of the conditions, restrictions and performance criteria which were applicable to the Shares subject to the Award or Option, as the case may be, prior to such
Change in Capitalization. 
  

	13.	Effect of Certain Transactions; Effect of Change in Control. 

 (a) Effect of Certain
Transactions. Subject to Sections 5.10, 7.7, 8.2(b) and 9.4 or as otherwise provided in an Agreement, in the event of (a) the liquidation or dissolution of the Company or (b) a merger or consolidation of the Company (a
“Transaction”), the Plan and the Options and Awards issued hereunder shall continue in effect in accordance with their respective terms, except that following a Transaction either (i) each outstanding Option or

  
 20 

 
Award shall be treated as provided for in the agreement entered into in connection with the Transaction or (ii) if not so provided in such agreement, each Optionee and Grantee shall be
entitled to receive in respect of each Share subject to any outstanding Options or Awards, as the case may be, upon exercise of any Option or payment or transfer in respect of any Award, the same number and kind of stock, securities, cash, property
or other consideration that each holder of a Share was entitled to receive in the Transaction in respect of a Share; provided, however, that such stock, securities, cash, property, or other consideration shall remain subject to all of the
conditions, restrictions and performance criteria which were applicable to the Options and Awards prior to such Transaction. For the avoidance of doubt, the Committee may, without the consent of any Optionee or Grantee, provide for the cancellation
of outstanding Awards in connection with a Transaction in exchange for the payment in cash or property equal in value to the Fair Market Value of the Shares underlying such Awards, less, in the case of Options (and Stock Appreciation Rights), the
aggregate exercise price (or Grant Price) thereof; provided that Options with an aggregate exercise price that is equal to or in excess of the aggregate Fair Market Value of the Shares underlying such Options, and Stock Appreciation Rights
whose Grant Price is equal to or in excess of the Fair Market Value of a Share to which such Stock Appreciation Rights relate, may be cancelled in connection with such Transaction without any consideration being paid in respect thereof. The
treatment of any Option or Award as provided in this Section 13(a) shall be conclusively presumed to be appropriate for purposes of Section 12. 

(b) Effect of Change in Control. Notwithstanding any other provision of the Plan to the contrary, in the event of a Change in Control,
the following provisions of this Section 13(b) shall apply except to the extent an Option or Award Agreement provides for a different treatment (in which case the Option or Award Agreement shall govern and this Section 13(b) shall not be
applicable): 
 (i) If and to the extent that outstanding Options or Awards under the Plan (A) are assumed by the
successor corporation (or affiliate thereto) or continued or (B) are replaced with equity awards that preserve the existing value of the Options or Awards at the time of the Change in Control and provide for subsequent payout in accordance with
a vesting schedule and Performance Objectives, as applicable, that are the same or more favorable to the Participants than the vesting schedule and Performance Objectives applicable to the Options or Awards, then all such Options or Awards or such
substitutes thereof shall remain outstanding and be governed by their respective terms and the provisions of the Plan, subject to Section 13(b)(iv) below. 

(ii) If and to the extent that outstanding Options or Awards under the Plan are not assumed, continued or replaced in
accordance with Section 13(b)(i) above, then upon the Change in Control the following treatment (referred to as “Change-in-Control Treatment”) shall apply to such Options or Awards: (A) outstanding Options and Stock Appreciation
Rights shall immediately vest and become exercisable; (B) the restrictions and other conditions applicable to outstanding Restricted Shares, Restricted Stock Units and Stock Awards, including vesting requirements, shall immediately lapse; such
Awards shall be free of all restrictions and fully vested; and, with respect to Restricted Stock Units, shall be payable immediately in accordance with their terms or, if later, as of the earliest permissible date under Code Section 409A; and
(C) outstanding Performance Awards granted under the Plan shall immediately vest and shall become immediately payable in accordance with their terms as if the Performance Objectives have been achieved at the target performance level. 

  
 21 

 (iii) If and to the extent that outstanding Options or Awards under the Plan are
not assumed, continued or replaced in accordance with Section 13(b)(i) above, then in connection with the application of the Change-in-Control Treatment set forth in Section 13(b)(ii) above, the Board may, in its sole discretion, provide
for cancellation of such outstanding Awards at the time of the Change in Control in which case a payment of cash, property or a combination thereof shall be made to each such Optionee or Grantee upon the consummation of the Change in Control that is
determined by the Board in its sole discretion and that is at least equal to the excess (if any) of the value of the consideration that would be received in such Change in Control by the holders of the Company’s securities relating to such
Options or Awards over the exercise or purchase price (if any) for such Options or Awards (except that, in the case of an Option or Stock Appreciation Right, such payment shall be limited as necessary to prevent the Option or Stock Appreciation
Right from being subject to the excise tax under Code Section 409A). 
 (iv) If and to the extent that
(A) outstanding Options or Awards are assumed, continued or replaced in accordance with Section 13(b)(i) above and (B) a Optionee’s or Grantee’s employment with, or performance of services for, the Company or any of its
Subsidiaries or successors is terminated by the Company or such Subsidiary or successor for any reasons other than Cause or by such Optionee or Grantee for Good Reason, in each case, within the two-year period commencing on the Change in Control,
then, as of the date of such Participant’s termination, the Change-in-Control Treatment set forth in Section 13(b)(ii) above shall apply to all assumed or replaced Options or Awards of such Participant then outstanding. 

(v) Outstanding Options or Stock Appreciation Rights that are assumed, continued or replaced in accordance with
Section 13(b)(i) may be exercised by the Optionee or Grantee in accordance with the applicable terms and conditions of such Option or Award as set forth in the applicable Agreement or elsewhere; provided, however, that Options or Stock
Appreciation Rights that become exercisable in accordance with Section 13(b)(iv) may be exercised until the expiration of the original full term of such Option or Stock Appreciation Right notwithstanding the other original terms and conditions
of such Award, to the extent allowed without such Option or Stock Appreciation Right becoming subject to the excise tax under Code Section 409A. 
  

	14.	Interpretation. 

 Following the required registration of any equity security of the Company
pursuant to Section 12 of the Exchange Act: 
 (a) The Plan is intended to comply with Rule 16b-3 promulgated under the Exchange Act
and the Committee shall interpret and administer the provisions of the Plan or any Agreement in a manner consistent therewith. Any provisions inconsistent with such Rule shall be inoperative and shall not affect the validity of the Plan. 

(b) Unless otherwise expressly stated in the relevant Agreement, each Option, Stock Appreciation Right and Performance Award granted under the
Plan is intended to be Performance-Based Compensation. The Committee shall not be entitled to exercise any discretion otherwise authorized hereunder with respect to such Options or Awards if the ability to exercise such discretion or the exercise of
such discretion itself would cause the compensation attributable to such Options or Awards to fail to qualify as Performance-Based Compensation. 

  
 22 

 (c) To the extent that any legal requirement of Section 16 of the Exchange Act or
Section 162(m) of the Code as set forth in the Plan ceases to be required under Section 16 of the Exchange Act or Section 162(m) of the Code, that Plan provision shall cease to apply. 

 

	15.	Termination and Amendment of the Plan or Modification of Options and Awards. 

 15.1 Plan
Amendment or Termination. The Plan shall terminate on the day preceding the tenth anniversary of the Restatement Effective Date and no Option or Award may be granted thereafter. The Board may sooner terminate the Plan and the Board, subject to
Section 7, may at any time and from time to time amend, modify or suspend the Plan; provided, however, that: 
 (a) no such
amendment, modification, suspension or termination shall impair or adversely alter any Options or Awards theretofore granted under the Plan, except with the written consent of the applicable Optionee or Grantee, nor shall any amendment,
modification, suspension or termination deprive any Optionee or Grantee of any Shares which he or she may have acquired through or as a result of the Plan; and 

(b) to the extent necessary under any applicable law, regulation or exchange requirement with which the Committee determines it is necessary
or desirable for the Company to comply, no amendment shall be effective unless approved by the stockholders of the Company in accordance with any such law, regulation or exchange requirement. 

15.2 Modification of Options and Awards. No modification of an Option or Award shall adversely alter or impair any rights or
obligations under the Option or Award without the written consent of the Optionee or Grantee, as the case may be. 
  

	16.	Non-Exclusivity of the Plan. 

 The adoption of the Plan by the Board shall not be construed as
amending, modifying or rescinding any previously approved incentive arrangement or as creating any limitations on the power of the Board to adopt such other incentive arrangements as it may deem desirable, including, without limitation, the granting
of stock options otherwise than under the Plan, and such arrangements may be either applicable generally or only in specific cases. 
  

	17.	Limitation of Liability. 

 As illustrative of the limitations of liability of the Company, but
not intended to be exhaustive thereof, nothing in the Plan shall be construed to: 
 (a) give any person any right to be granted an Option
or Award other than at the sole discretion of the Committee; 
 (b) give any person any rights whatsoever with respect to Shares except as
specifically provided in the Plan; 
 (c) limit in any way the right of the Company or any Subsidiary to terminate the employment of any
person at any time; or 

  
 23 

 (d) be evidence of any agreement or understanding, expressed or implied, that the Company will
employ any person at any particular rate of compensation or for any particular period of time. 
  

	18.	Regulations and Other Approvals; Governing Law. 

 18.1 Except as to matters of federal law, the
Plan and the rights of all persons claiming hereunder shall be construed and determined in accordance with the laws of the State of Delaware without giving effect to conflicts of laws principles thereof. 

18.2 The obligation of the Company to sell or deliver Shares with respect to Options and Awards granted under the Plan shall be subject to all
applicable laws, rules and regulations, including all applicable federal and state securities laws, and the obtaining of all such approvals by governmental agencies as may be deemed necessary or appropriate by the Committee. 

18.3 The Board may make such changes as may be necessary or appropriate to comply with the rules and regulations of any government authority,
or to obtain for Eligible Individuals granted Incentive Stock Options the tax benefits under the applicable provisions of the Code and regulations promulgated thereunder. 

18.4 Each Option and Award is subject to the requirement that, if at any time the Committee determines, in its discretion, that the listing,
registration or qualification of Shares issuable pursuant to the Plan is required by any securities exchange or under any state or federal law, or the consent or approval of any governmental regulatory body is necessary or desirable as a condition
of, or in connection with, the grant of an Option or Award or the issuance of Shares, no Options or Awards shall be granted or payment made or Shares issued, in whole or in part, unless listing, registration, qualification, consent or approval has
been effected or obtained free of any conditions as acceptable to the Committee. 
 18.5 Notwithstanding anything contained in the Plan or
any Agreement to the contrary, in the event that the disposition of Shares acquired pursuant to the Plan is not covered by a then current registration statement under the Securities Act of 1933, as amended (the “Securities Act”), and is
not otherwise exempt from such registration, such Shares shall be restricted against transfer to the extent required by the Securities Act and Rule 144 or other regulations thereunder. The Committee may require any individual receiving Shares
pursuant to an Option or Award granted under the Plan, as a condition precedent to receipt of such Shares, to represent and warrant to the Company in writing that the Shares acquired by such individual are acquired without a view to any distribution
thereof and will not be sold or transferred other than pursuant to an effective registration thereof under the Securities Act or pursuant to an exemption applicable under the Securities Act or the rules and regulations promulgated thereunder. The
certificates evidencing any such Shares shall be appropriately amended or have an appropriate legend placed thereon to reflect their status as restricted securities as aforesaid. 

18.6 Compliance With Section 409A. All Options and Awards granted under the plan are intended either not to be subject to
Section 409A of the Code or, if subject to Section 409A of the Code, to be administered, operated and construed in compliance with Section 409A of the Code and any guidance issued thereunder. Notwithstanding this or any other
provision of the Plan to the contrary, the Committee may amend the Plan or any Option or Award granted hereunder in any manner, or take any other action, that it determines, in its sole discretion, is necessary, appropriate or advisable to cause the
Plan or any Option or Award granted 

  
 24 

 
hereunder to comply with Section 409A and any guidance issued thereunder. In the event that it is reasonably determined by the Board or Committee that, as a result of Section 409A of
the Code, payments in respect of any Award under the Plan may not be made at the time contemplated by the terms of the Plan or the relevant Agreement, as the case may be, without causing the Participant holding such Award to be subject to taxation
under Section 409A of the Code, the Company will make such payment on the first day that would not result in the Participant incurring any tax liability under Section 409A of the Code; which, if the Participant is a “specified
employee” within the meaning of the Section 409A, generally shall be the first day following the six-month period beginning on the date of Participant’s termination of employment. Any such action, once taken, shall be deemed to be
effective from the earliest date necessary to avoid a violation of Section 409A and shall be final, binding and conclusive on all Eligible Individuals and other individuals having or claiming any right or interest under the Plan. Although the
Company intends to administer the Plan so that Awards will be exempt from, or will comply with, the requirements of Section 409A of the Code, the Company does not warrant that any Award under the Plan will qualify for favorable tax treatment
under Section 409A of the Code or any other provision of federal, state, local or foreign law. The Company shall not be liable to any Participant for any tax, interest, or penalties that Participant might owe as a result of the grant, holding,
vesting, exercise, or payment of any Award under the Plan. 
  

	19.	Miscellaneous. 

 19.1 Forfeiture and Clawback Provisions. Pursuant to its general
authority to determine the terms and conditions applicable to Options and Awards granted under the Plan, the Committee shall have the right to provide, in an Agreement, or to require a Participant to agree by separate written or electronic
instrument at or after grant, that all Options and Awards (including any proceeds, gains or other economic benefit actually or constructively received by the Participant upon any receipt or exercise of any Option or Award or upon the receipt or
resale of any Shares underlying the Option or Award) will be subject to repayment or reimbursement to the extent set forth in any recoupment or clawback provisions which may be included in any such Agreement or separate instrument. In addition,
without limiting the foregoing, any Option or Award granted pursuant to this Plan shall be subject to repayment or reimbursement by the Participant to the Company (i) to the extent provided in the Company’s current “Clawback
Policy,” as it may be amended from time to time, (ii) to the extent that Participant in the future becomes subject to any other recoupment or clawback policy hereafter adopted by the Company, including any such policy (or amended version
of the Company’s current Clawback Policy) adopted by the Company to comply with the requirements of any applicable laws, rules or regulations, including pursuant to final SEC rules under the Dodd-Frank Wall Street Reform and Consumer Protection
Act, or (iii) to the extent provided under any applicable laws which impose mandatory recoupment, under circumstances set forth in such applicable laws, including the Sarbanes-Oxley Act of 2002. 

19.2 Multiple Agreements. The terms of each Option or Award may differ from other Options or Awards granted under the Plan at the same
time or at some other time. The Committee may also grant more than one Option or Award to a given Eligible Individual during the term of the Plan, either in addition to, or in substitution for, one or more Options or Awards previously granted to
that Eligible Individual. 
 19.3 Beneficiary Designation. Each Optionee or Grantee may, from time to time, name one or more
individuals (each, a “Beneficiary”) to whom any benefit under the Plan is to be paid or who may exercise any rights of the Optionee or Grantee under any Option or Award granted under the Plan in the event of the Optionee’s or
Grantee’s death before he or she receives any 

  
 25 

 
or all of such benefit or exercises such Option. Each such designation shall revoke all prior designations by the same Optionee or Grantee, shall be in a form prescribed by the Company, and will
be effective only when filed by the Optionee or Grantee in writing with the Company during the Optionee’s or Grantee’s lifetime. In the absence of any such designation, benefits remaining unpaid at the Optionee’s or Grantee’s
death and rights to be exercised following the Optionee’s or Grantee’s death shall be paid to or exercised by the Optionee’s or Grantee’s estate. 

19.4 Withholding of Taxes. 

(a) At such times as an Optionee or Grantee recognizes taxable income in connection with the receipt of Shares or cash hereunder (a
“Taxable Event”), the Optionee or Grantee shall pay to the Company an amount equal to the federal, state and local income taxes and other amounts as may be required by law to be withheld by the Company in connection with the Taxable Event
(the “Withholding Taxes”) prior to the issuance, or release from escrow, of such Shares or the payment of such cash. The Company shall have the right to deduct from any payment of cash to an Optionee or Grantee an amount equal to the
Withholding Taxes in satisfaction of the obligation to pay Withholding Taxes. The Committee may provide in an Agreement evidencing an Option or Award at the time of grant or thereafter that the Optionee or Grantee, in satisfaction of the obligation
to pay Withholding Taxes to the Company, may elect to have withheld a portion of the Shares issuable to him or her pursuant to the Option or Award having an aggregate Fair Market Value equal to the Withholding Taxes. In the event Shares are withheld
by the Company to satisfy any obligation to pay Withholding Taxes, such Shares shall be retired and cancelled and shall not thereafter be available to grant an Option or Award with respect thereto. In determining the procedures by which Shares will
be withheld for Withholding Taxes, to the extent required to avoid the Company’s incurring an adverse accounting charge, the amount of any Shares so withheld shall not exceed the amount necessary to satisfy Withholding Taxes determined using
the minimum statutory withholding rates for federal, state, local and/or foreign tax purposes, including payroll taxes, that are applicable to supplemental taxable income. 

(b) If an Optionee makes a disposition, within the meaning of Section 424(c) of the Code and regulations promulgated thereunder, of any
Share or Shares issued to such Optionee pursuant to the exercise of an Incentive Stock Option within the two-year period commencing on the day after the date of the grant or within the one-year period commencing on the day after the date of transfer
of such Share or Shares to the Optionee pursuant to such exercise, the Optionee shall, within ten (10) days of such disposition, notify the Company thereof, by delivery of written notice to the Company at its principal executive office. 

19.5 Effective Date. The effective date of this Plan shall be March 16, 2016 (the “Restatement Effective Date”), subject
only to the approval by the holders of a majority of the securities of the Company entitled to vote thereon, in accordance with the applicable laws, within twelve (12) months of the adoption of the Plan by the Board. 

  
 26EX-10.1

 Exhibit 10.1 

EXECUTIVE EMPLOYMENT AGREEMENT 

This EXECUTIVE EMPLOYMENT AGREEMENT (“Agreement”) is made as of May [    ], 2016, by and between
Oncothyreon Inc. (the “Company”) and [                    ] (“Executive”). 

R E C I T A L S 
 WHEREAS,
the Company and Executive are parties to that certain Offer Letter, dated and effective as of [                    ], and as amended from time to
time, pursuant to which Executive is employed by the Company (the “Offer Letter”); 
 WHEREAS, the Company and Executive
wish to amend and restate the Offer Letter pursuant to the terms of this Agreement, which shall replace and supersede the Offer Letter; 

WHEREAS, the Company has issued, or will issue, Executive stock options under any equity incentive compensation plan(s) sponsored by the
Company with such issuance contingent upon Executive’s execution of this Agreement; 
 WHEREAS, this Agreement contains various
enhancements to the terms and conditions of Executive’s employment, the sufficiency of which, the parties hereto acknowledge as good and valuable consideration for the amendment and restatement of the Offer Letter; and 

WHEREAS, the Company has authorized and approved the execution of this Agreement and Executive desires to be employed by the Company on the
terms and conditions set forth in this Agreement. 
 NOW, THEREFORE, in consideration of the foregoing recitals, the mutual covenants and
conditions herein, and other good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, the parties hereby agree as follows: 

A G R E E M E N T 
 1.
Employment and Term. Subject to the provisions of Section 5 below, Executive shall be employed by the Company as of the date of this Agreement (the “Effective Date”) and continue until terminated as described in
Section 5.1 (the “Term”) on the terms and subject to the conditions set forth in this Agreement. 
 2. Position,
Duties and Responsibilities; Location. 
 2.1 Position and Duties. Executive shall be employed as the
[                    ] of the Company. Executive shall have the duties, powers and authority as are commensurate with his position, including
such other duties and responsibilities as are reasonably delegated to him from time to time by the [                     (the
“                    ”)]. Executive shall report to the
[                    ]. 
 2.2
Exclusive Services and Efforts. Executive agrees to devote his efforts, energies, and skill to the discharge of the duties and responsibilities attributable to his position and, except as set forth herein, agrees to devote substantially
all of his professional time and attention exclusively to the business and affairs of the Company; provided, that nothing herein shall preclude Executive from accepting appointment to or serving or continuing to serve on any other
board of directors or trustees of any charitable organization; further provided, that such activities do not conflict with the obligations of Executive under the terms of the Employee Confidentiality, Invention Assignment and
Non-Compete Agreement or any other of Executive’s restrictive covenants with the Company or an affiliate, or materially interfere with the performance of Executive’s duties hereunder 

 3. Compensation. 

3.1 Base Salary. During the Term, the Company hereby agrees to pay to Executive an annualized base salary of
[                     ($        )] (the “Salary”), subject to all applicable Federal, state
and local income and employment taxes and other required or elected withholdings and deductions, payable in equal installments on the Company’s regularly-scheduled paydays as it is earned. Executive’s Salary will be reviewed at least
annually by the Compensation Committee (the “Compensation Committee”) of the Board of Directors of the Company (the “Board”) and, when appropriate as determined in the Compensation Committee’s discretion, may
be adjusted (in which case such adjusted amount shall be the “Salary” hereunder). 
 3.2 Annual Cash Bonus.

(a) For each calendar year that ends during the Term (subject to proration in accordance with Section 3.2(b)), Executive shall be
entitled to participate in any employee bonus plan sponsored by the Company with an incentive compensation target amount equal to
[                     (        %)] of Executive’s Salary (the “Annual Cash Bonus”);
provided, however, that the failure of the Company to award any such Annual Cash Bonus and/or other incentive compensation shall not give rise to any claim against the Company. The amount, if any, and timing of such Annual Cash
Bonus, shall be determined based upon the performance of the Company and Executive. The amount, if any, and timing of the Annual Cash Bonus shall be determined by the Compensation Committee or its delegate in its sole discretion;
provided, that any such Annual Cash Bonus shall be paid to Executive no later than March 15 of the calendar year following the year in which the Annual Cash Bonus was earned, subject to any payment delays that would be permitted
without causing this bonus right to cease to qualify as a short-term deferral that is exempt from Section 409A of the Internal Revenue Code, as amended (the “Code”). Except as otherwise set forth in this Section 3.2, payment
of the Annual Cash Bonus is conditioned upon Executive remaining employed with the Company as of the payment date. 
 (b) If
Executive’s employment terminates before the end of the applicable bonus performance period pursuant to Section 5.2 or 5.3 below, upon the satisfaction of the requirements of Section 5.7, Executive shall be entitled to a
portion of the Annual Cash Bonus determined by multiplying Executive’s target Annual Cash Bonus amount by a fraction equal to the number of days of Executive’s employment during such applicable period divided by the total number of days in
the applicable bonus performance period (the “Pro-Rated Cash Bonus”). Payment of any bonus under this Section 3.2(b) shall be made in accordance with Section 5.2 or 5.3
below. 
 3.3 Annual Equity Award. Executive will be eligible for annual grants of long-term incentive and equity compensation
awards at the Compensation Committee’s good faith discretion under any equity incentive compensation plan sponsored by the Company from time to time. 

3.4 Change in Control Bonus. Executive shall be eligible for a special, one-time bonus at the Compensation Committee’s discretion
upon a Change in Control (the “Change in Control Bonus”); provided, however, that the failure of the Company to award any such Change in Control Bonus shall not give rise to any claim against the Company. The
amount, if any, and timing of the Change in Control Bonus shall be determined by the Compensation Committee or its delegate in its sole discretion; provided, that any such Change in Control Bonus shall be paid to Executive within
ninety (90) days following a Change in Control. 

  
 - 2 - 

 4. Employee Benefits. 

4.1 Participation in Benefit Plans. During the Term, Executive shall be entitled to participate in such health, group insurance,
welfare, pension, and other employee benefit plans, programs and arrangements as are made generally available from time to time to executives of the Company (which shall include customary health, life insurance and disability plans), such
participation in each case to be on terms and conditions no less favorable to Executive than to other executives of the Company generally. 

4.2 Fringe Benefits, Perquisites and Vacations. During his employment by the Company, Executive shall be entitled to participate
in all fringe benefits and perquisites made available to other executives of the Company, such participation to be at levels, and on terms and conditions, that are commensurate with his position and responsibilities at the Company and that are no
less favorable than those applying to other executives of the Company at the same level. 
 4.3 Vacation. Executive shall be
entitled to earn and use vacation pursuant to the Company’s vacation policy as in effect from time to time for executives of the Company; provided that Executive shall be entitled to four (4) weeks of vacation per annum. 

4.4 Reimbursement of Expenses. The Company shall reimburse Executive for all reasonable business and travel expenses incurred in the
performance of his job duties and the promotion of the Company’s business promptly upon presentation of appropriate supporting documentation and otherwise in accordance with the expense reimbursement policy of the Company. 

5. Termination. 
 5.1
General. The Company may terminate Executive’s employment for any reason or no reason, and Executive may terminate his employment for any reason or no reason, in either case subject only to the terms of this Agreement. In the event of
the termination of Executive’s employment hereunder for any reason, he shall promptly resign from any position he then holds that is affiliated with the Company or that he was holding at the Company’s request. For purposes of this
Agreement, the following terms have the following meanings: 
 (a) “Accrued Obligations” shall mean: (i) Executive’s
earned but unpaid Salary through the Termination Date; (ii) a lump-sum payment in respect of accrued but unused vacation days at Executive’s per-business-hourly Salary rate in effect as of the Termination Date; (iii) any unpaid expense or other
reimbursements due pursuant to Section 4.4 hereof or otherwise, and (iv) reimbursement of contributions to the Company’s ESPP to the extent those contributions have not been converted to shares as of the Termination Date. 

(b) “Cause” shall mean (i) Executive willfully engages in illegal conduct or gross misconduct which is injurious to the
Company or an affiliated company; (ii) Executive is convicted of, or pleads guilty or nolo contendere to, a felony or a crime involving moral turpitude; (iii) Executive engages in fraud, misappropriation, embezzlement or any other act
or acts of dishonesty resulting or intended to result directly or indirectly in a gain or personal enrichment at the expense of the Company or an affiliated company; (iv) Executive’s material breach of any written policy of the Company or an
affiliated Company; or (v) Executive refuses to perform, or repeatedly fails to undertake good faith efforts to perform, the duties or responsibilities reasonably assigned to him (consistent with Section 2) by the
[                    ], which non-performance has continued for thirty (30) days following Executive’s receipt of written notice from the Board
of such non-performance. 

  
 - 3 - 

 (c) “Change in Control” for purposes of this Agreement shall mean the first to
occur of any of the following, provided that for any distribution that is subject to Section 409A (as defined in Section 7.2), a Change in Control under this Agreement shall be deemed to occur only if such event also satisfies
the requirements under Treas. Regs. Section 1.409A-(i)(5): 
 (i) any Person becomes the “beneficial owner” (as defined in Rule
13d-3 of the United States Securities Exchange Act of 1934, as amended), directly or indirectly, of securities of the Company representing more than fifty percent (50%) of the total voting power represented by the Company’s then-outstanding
voting securities; provided, however, that the acquisition of additional securities by any one Person who is considered to own more than fifty percent (50%) of the total voting power of the securities of the Company will not be
considered a Change in Control; 
 (ii) the consummation of the sale, transfer or disposition by the Company of all or substantially all of
the Company’s assets; 
 (iii) the consummation of a merger or consolidation of the Company with any other corporation, other than a
merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or
its parent) more than fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation; 

(iv) any other transaction which qualifies as a “corporate transaction” under Section 424(a) of the Code wherein the
stockholders of the Company give up all of their equity interest in the Company (except for the acquisition, sale or transfer of all or substantially all of the outstanding shares of the Company); or 

(v) a change in the effective control of the Company that occurs on the date that a majority of members of the Board is replaced during any
twelve (12) month period by members of the Board whose appointment or election is not endorsed by a majority of the members of the Board prior to the date of the appointment or election; provided, however, that if any Person is
considered to be in effective control of the Company, the acquisition of additional control of the Company by the same Person will not be considered a Change in Control. 

For purposes of this Section 5.1(c), Persons will be considered to be acting as a group if they are owners of a corporation that enters into a merger,
consolidation, purchase or acquisition of stock, or similar business transaction with the Company. 
 (d) “Disability”
shall mean that Executive has been unable, with or without reasonable accommodation and due to physical or mental incapacity, to substantially perform his duties and responsibilities hereunder for one hundred eighty (180) consecutive days. 

(e) “Good Reason” shall mean the occurrence of any of the following events without Executive’s express prior written
consent: (i) material diminution of Executive’s job responsibilities as such responsibilities exist as of the Effective Date; provided, however, that a change in Executive’s title and/or who he reports to within twelve (12)
months following the Effective Date shall not be considered Good Reason unless such change occurs following a Change in Control; (ii) the material reduction in Executive’s Salary, unless such reduction is part of a reduction in compensation for
all employees of the Company in general; or (iii) relocation of Executive’s principal office, or principal place of employment, to a location that is more than fifty (50) miles from Executive’s principal office, or principal place of
employment. 

  
 - 4 - 

 A termination of employment by Executive for Good Reason shall be effectuated by giving the
Company written notice (“Notice of Termination for Good Reason”), not later than thirty (30) days following the occurrence of the circumstance that constitutes Good Reason, setting forth in reasonable detail the specific conduct of
the Company that constitutes Good Reason. The Company shall be entitled, during the thirty (30) day period following receipt of a Notice of Termination for Good Reason, to cure the circumstances that gave rise to Good Reason, provided
that the Company shall be entitled to waive its right to cure or reduce the cure period by delivery of written notice to that effect to Executive (such thirty (30) day or shorter period, the “Cure Period”). If, during the
Cure Period, such circumstance is remedied, Executive will not be permitted to terminate employment for Good Reason as a result of such circumstance. If, at the end of the Cure Period, the circumstance that constitutes Good Reason has not been
remedied, Executive will be entitled to terminate employment for Good Reason during the ten (10) day period that follows the end of the Cure Period. If Executive does not terminate employment during such ten (10) day period, Executive will not be
permitted to terminate employment for Good Reason as a result of such circumstance. 
 (f) “Person” shall mean a
“person” as such term is used in Sections 13(d) and 14(d) of the United States Securities Exchange Act of 1934, as amended. 

(g) “Termination Date” shall mean the date on which Executive’s employment hereunder terminates in accordance with this
Agreement. 
 5.2 Termination by the Company Without Cause. In the event that Executive’s employment is terminated by the
Company without Cause, the Term shall expire on the Termination Date and Executive shall be entitled to: 
 (a) a single sum cash amount,
payable not later than the sixtieth (60th) day following his Termination Date, in an amount equal to Nine (9) months of Executive’s Salary as in effect immediately prior to the Termination Date; 

(b) the greater of (i) the Pro-Rated Cash Bonus described in Section 3.2(b); and (ii) seventy-five percent (75%) of Executive’s
target Annual Cash Bonus, payable on the sixtieth (60th) day following his Termination Date; 
 (c) continued medical (health, dental,
prescription drug and vision) benefits to the same extent in which Executive participated prior to the Termination Date (with Executive required to pay the amount Executive would have been required to pay for such coverage had Executive remained an
active employee at such time) for a period of Nine (9) months following the Termination Date; provided, however, if the Company cannot provide, for any reason, Executive or his dependents with the opportunity to participate in the
benefits to be provided pursuant to this paragraph, the Company shall pay to Executive a single sum cash payment, payable within sixty (60) days following the date the Company cannot provide such benefits, in an amount equal to the fair market value
of the benefits to be provided pursuant to this paragraph; and 
 (d) the Accrued Obligations. 

5.3 Termination by Executive With Good Reason. In the event that Executive’s employment is terminated by Executive for Good
Reason, the Term shall expire on the Termination Date and Executive shall be entitled to: 
 (a) a single sum cash amount, payable not
later than the sixtieth (60th) day following his Termination Date, in an amount equal to Nine (9) months of Executive’s Salary as in effect immediately prior to the Termination Date; 

  
 - 5 - 

 (b) the Pro-Rated Cash Bonus described in Section 3.2(b) payable on the sixtieth (60th)
day following his Termination Date; 
 (c) continued medical (health, dental, prescription drug and vision) benefits to the same extent in
which Executive participated prior to the Termination Date (with Executive required to pay the amount Executive would have been required to pay for such coverage had Executive remained an active employee at such time) for a period of Nine (9) months
following the Termination Date; provided, however, if the Company cannot provide, for any reason, Executive or his dependents with the opportunity to participate in the benefits to be provided pursuant to this paragraph, the Company
shall pay to Executive a single sum cash payment, payable within sixty (60) days following the date the Company cannot provide such benefits, in an amount equal to the fair market value of the benefits to be provided pursuant to this paragraph; and

 (d) the Accrued Obligations. 

5.4 Death and Disability. Executive’s employment shall terminate in the event of his death, and either Executive or the Company
may terminate Executive’s employment in the event of his Disability (provided that no termination of Executive’s employment hereunder for Disability shall be effective unless the party terminating Executive’s employment
first gives at least fifteen (15) days’ written notice of such termination to the other party). In the event that Executive’s employment hereunder is terminated due to his death or Disability, the Term shall expire on the Termination Date
and he and/or his estate or beneficiaries (as the case may be) shall be entitled to the Accrued Obligations. 
 5.5 Termination by the
Company For Cause or by Executive Without Good Reason. In the event that Executive’s employment hereunder is terminated by Executive without Good Reason or by the Company for Cause, the Term shall expire as of the Termination Date and
Executive shall be entitled to the Accrued Obligations. 
 5.6 Due to Change in Control. In the event that within twelve (12) months
following a Change in Control Executive terminates his employment hereunder with Good Reason or the Company (or its successor) terminates Executive’s employment hereunder without Cause, then, in lieu of the payments otherwise due to Executive
under Section 5.2 or 5.3 above, the Term shall expire on the Termination Date and Executive shall be entitled to: 
 (a) a
single sum cash amount, payable on the sixtieth (60th) day following his Termination Date, in an amount equal to Eighteen (18) months of Executive’s Salary as in effect immediately prior to the Termination Date; 

(b) one hundred percent (100%) of Executive’s target Annual Cash Bonus described in Section 3.2(a) payable on the sixtieth (60th)
day following his Termination Date; 
 (c) continued medical (health, dental, prescription drug and vision) benefits to the same extent in
which Executive participated prior to the Termination Date (with Executive required to pay the amount Executive would have been required to pay for such coverage had Executive remained an active employee at such time) for a period of Eighteen (18)
months following the Termination Date; provided, however, if the Company cannot provide, for any reason, Executive or his dependents with the opportunity to participate in the benefits to be provided pursuant to this paragraph, the
Company shall pay 

  
 - 6 - 

 
to Executive a single sum cash payment, payable within sixty (60) days following the date the Company cannot provide such benefits, in an amount equal to the fair market value of the benefits to
be provided pursuant to this paragraph; 
 (d) full vesting, exercisability and non-forfeitability, as applicable, as of his Termination
Date, of any outstanding, unvested equity or equity-based awards; and 
 (e) the Accrued Obligations. 

5.7 Release. Executive’s entitlement to the payments described in this Section 5 is expressly contingent upon Executive
first providing the Company with a signed release in substantially the form attached hereto as Exhibit A (the “Release”). In order to be effective, such Release must be delivered by Executive to the Company no later than
forty-five (45) days following the Termination Date. 
 6. Section 280G. 

6.1 If any payment or benefit (including payments and benefits pursuant to this Agreement) that Executive would receive in connection with a
Change in Control from the Company or otherwise (“Transaction Payment”) would (a) constitute a “parachute payment” within the meaning of Section 280G of the Code; and (b) the net after-tax benefit that Executive would
receive by reducing the Transaction Payments to three times the “base amount,” as defined in Section 280G(b)(3) of the Code, (the “Parachute Threshold”) is greater than the net after-tax benefit Executive would receive if
the full amount of the Transaction Payments were paid to Executive, then the Transaction Payments payable to Executive shall be reduced (but not below zero) so that the Transaction Payments due to Executive do not exceed the amount of the Parachute
Threshold, reducing first any Transaction Payments under Section 5.6(a) hereof. 
 6.2 Unless Executive and the Company otherwise
agree in writing, any determination required under this section shall be made in writing by the Company’s independent public accountants (the “Accountants”), whose determination shall be conclusive and binding upon Executive
and the Company for all purposes. The Accountants may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application of Sections 280G and 4999 of the Code.
The Accountants shall provide detailed supporting calculations to the Company and Executive as requested by the Company or Executive at least thirty (30) days prior to the date the excise tax imposed by Section 4999 of the Code (including any
interest, penalties or additions to tax relating thereto) is required to be paid by Executive or withheld by the Company. Executive and the Company shall furnish to the Accountants such information and documents as the Accountants may reasonably
request in order to make a determination under this section. The Company shall bear all costs the Accountants may reasonably incur in connection with any calculations contemplated by this section as well as any costs incurred by Executive with the
Accountants for tax planning under Sections 280G and 4999 of the Code. 
 6.3 The Company hereby agrees that, for purposes of determining
whether any Transaction Payment would be subject to the excise tax under Section 4999 of the Code, the non-compete set forth in Exhibit B shall be treated as an agreement for the performance of personal services. The Company hereby agrees to
indemnify, defend, and hold harmless Executive from and against any adverse impact, tax, penalty, or excise tax resulting from the Company or Accountants’ attribution of a value to the non-compete set forth in Exhibit B that is less than the
total compensation amount disclosed under Item 402(c) of Securities and Exchange Commission Regulation S-K for 2015 (as reported in the 2016 annual report or proxy statement), to the extent the use of such lesser amount results in a larger excise
tax under Section 4999 of the Code than Executive would have been subject to had the Company or 

  
 - 7 - 

 
Accountants attributed a value to the non-compete set forth in Exhibit B that is at least equal to the total compensation amount disclosed under Item 402(c) of Securities and Exchange Commission
Regulation S-K for 2015. 
 7. Tax Matters. 

7.1 The Company shall withhold all applicable federal, state and local taxes, social security and workers’ compensation contributions and
other amounts as may be required by law with respect to compensation payable to Executive pursuant to this Agreement. 
 7.2 Notwithstanding
anything herein to the contrary, this Agreement is intended to be interpreted and applied so that the payment of the benefits set forth herein either shall either be exempt from the requirements of Section 409A of the Code
(“Section 409A”) or shall comply with the requirements of such provision. Notwithstanding any provision of this Agreement to the contrary, if Executive is a “specified employee” within the meaning of Section 409A, any
payments or arrangements due upon a termination of Executive’s employment under any arrangement that constitutes a “nonqualified deferral of compensation” within the meaning of Section 409A and which do not otherwise qualify under the
exemptions under Treas. Regs. Section 1.409A-1 (including without limitation, the short-term deferral exemption or the permitted payments under Treas. Regs. Section 1.409A-1(b)(9)(iii)(A)), shall be delayed and paid or provided on the earlier of (a)
the date which is six (6) months after Executive’s “separation from service” (as such term is defined in Section 409A and the regulations and other published guidance thereunder) for any reason other than death; and (b) the date of
Executive’s death. 
 7.3 After any Termination Date, Executive shall have no duties or responsibilities that are inconsistent with
having a “separation from service” within the meaning of Section 409A as of the Termination Date and, notwithstanding anything in the Agreement to the contrary, distributions upon termination of employment of nonqualified deferred
compensation may only be made upon a “separation from service” as determined under Section 409A and such date shall be the Termination Date for purposes of this Agreement. Each payment under this Agreement or otherwise shall be treated as
a separate payment for purposes of Section 409A. In no event may Executive, directly or indirectly, designate the calendar year of any payment to be made under this Agreement which constitutes a “nonqualified deferral of compensation”
within the meaning of Section 409A and to the extent an amount is payable within a time period, the time during which such amount is paid shall be in the discretion of the Company. 

7.4 Any amounts otherwise payable to Executive following a termination of employment that are not so paid by reason of this Section 7
shall be paid as soon as practicable following, and in any event within thirty (30) days following, the date that is six (6) months after Executive’s separation from service (or, if earlier, the date of Executive’s death) together with
interest on the delayed payment at the Company’s cost of borrowing. All reimbursements and in-kind benefits provided under this Agreement shall be made or provided in accordance with the requirements of Section 409A. 

7.5 To the extent that any reimbursements pursuant to Section 4 or otherwise are taxable to Executive, any reimbursement payment due to
Executive pursuant to such Section shall be paid to Executive on or before the last day of Executive’s taxable year following the taxable year in which the related expense was incurred. The reimbursements pursuant to Section 4 or
otherwise are not subject to liquidation or exchange for another benefit and the amount of such reimbursements that Executive receives in one taxable year shall not affect the amount of such reimbursements that Executive receives in any other
taxable year. 

  
 - 8 - 

 8. Confidentiality, Invention Assignment and Non-Competition Agreement. Executive agrees
to be bound by the terms of the Employee Confidentiality, Invention Assignment and Non-Compete Agreement, a copy of which is attached hereto as Exhibit B and incorporated herein by reference (the “Non-Compete Agreement”).
Except as expressly set forth in this Agreement and the Non-Compete Agreement, Executive shall be subject to no contractual or similar restrictions on his right to terminate his employment hereunder or on his
activities after the Termination Date. 
 9. Non-Disparagement. During and after the Term, Executive agrees not to make any statement
that criticizes, ridicules, disparages, or is otherwise derogatory of the Company; provided, however, that nothing in this Agreement shall restrict Executive from making truthful statements (a) when required by law, subpoena, court
order or the like; or (b) when requested by a governmental, regulatory, or similar body or entity. 
 10. Notices. Except as
otherwise specifically provided herein, any notice, consent, demand or other communication to be given under or in connection with this Agreement shall be in writing and shall be deemed duly given when delivered personally, when transmitted by
facsimile transmission, one (1) day after being deposited with Federal Express or other nationally recognized overnight delivery service or three (3) days after being mailed by first class mail, charges or postage prepaid, properly addressed, if to
the Company, at its principal office, and, if to Executive, at his address set forth following his signature below. Either party may change such address from time to time by notice to the other. 

11. Governing Law. This Agreement shall be governed by and construed and interpreted in accordance with the laws of the State of
Washington, exclusive of any choice of law rules. 
 12. Arbitration; Legal Fees. 

12.1 Any dispute or controversy arising under or in connection with this Agreement (except with respect to injunctive relief under Section
8) shall be settled exclusively by arbitration in Washington, in accordance with the rules of the American Arbitration Association for employment disputes as then in effect. Judgment may be entered on the arbitrator’s award in any court
having jurisdiction. 
 12.2 In the event of any material contest or dispute relating to this Agreement or the termination of
Executive’s employment hereunder, each of the parties shall bear its own costs and expenses. 
 13. Amendments; Waivers. This
Agreement may not be modified or amended or terminated except by an instrument in writing, signed by Executive and a duly-authorized officer of the Company (other than Executive). By an instrument in writing similarly executed, either party may
waive compliance by the other party with any provision of this Agreement that such other party was or is obligated to comply with or perform; provided, however, that such waiver shall not operate as a waiver of, or estoppel with
respect to, any other or subsequent failure. No failure to exercise and no delay in exercising any right, remedy, or power hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any right, remedy, or power hereunder
preclude any other or further exercise thereof or the exercise of any other right, remedy, or power provided herein or by law or in equity. To be effective, any written waiver must specifically refer to the condition(s) or provision(s) of this
Agreement being waived. 
 14. Inconsistencies. In the event of any inconsistency between any provision of this Agreement and any
provision of any Company arrangement, the provisions of this Agreement shall control, unless Executive and the Company otherwise agree in a writing that expressly refers to the provision of this Agreement that is being waived. 

  
 - 9 - 

 15. Assignment. Except as otherwise specifically provided herein, neither party shall
assign or transfer this Agreement nor any rights hereunder without the consent of the other party, and any attempted or purported assignment without such consent shall be void; provided, however, that any assignment or transfer
pursuant to a merger or consolidation, or the sale or liquidation of all or substantially all of the business and assets of the Company shall be valid without the consent of Executive, so long as the assignee or transferee (a) is the successor to
all or substantially all of the business and assets of the Company; and (b) assumes the liabilities, obligations and duties of the Company, as contained in this Agreement, either contractually or as a matter of law. This Agreement shall otherwise
bind and inure to the benefit of the parties hereto and their respective successors, assigns, heirs, legatees, devisees, executors, administrators and legal representatives. 

16. Voluntary Execution; Representations. Executive acknowledges that (a) he has consulted with or has had the opportunity to consult
with independent counsel of his own choosing concerning this Agreement and has been advised to do so by the Company; and (b) he has read and understands this Agreement, is competent and of sound mind to execute this Agreement, is fully aware of the
legal effect of this Agreement, and has entered into it freely based on his own judgment and without duress. Executive represents and covenants that his employment hereunder and compliance with the terms and conditions hereof will not conflict with
or result in the breach by him of any agreement to which he is a party or by which he may be bound and in connection with his employment with the Company he will not engage in any unauthorized use of any confidential or proprietary information he
may have obtained in connection with his employment with any other employer. The Company represents and warrants that it is fully authorized, by any person or body whose authorization is required, to enter into this Agreement and to perform its
obligations under it. 
 17. Headings. The headings of the Sections and sub-sections contained in this Agreement are for convenience
only and shall not be deemed to control or affect the meaning or construction of any provision of this Agreement. 
 18.
Survivorship. Except as otherwise set forth in this Agreement, the respective rights and obligations of the parties shall survive any termination of Executive’s employment. 

19. Severability. Whenever possible, each provision or portion of any provision of this Agreement will be interpreted in such manner as
to be effective and valid under applicable law but the invalidity or unenforceability of any provision or portion of any provision of this Agreement in any jurisdiction shall not affect the validity or enforceability of the remainder of this
Agreement in that jurisdiction or the validity or enforceability of this Agreement, including that provision or portion of any provision, in any other jurisdiction. 

20. Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed an original, but all such
counterparts shall together constitute one and the same instrument. Signatures delivered by facsimile or PDF shall be effective for all purposes. 

21. Entire Agreement. This Agreement and the agreements described in the attached Exhibits contain the entire agreement of the parties
and supersedes all prior or contemporaneous negotiations, correspondence, understandings and agreements between the parties, regarding the subject matter of this Agreement. 

[Signature Page to Follow] 

  
 - 10 - 

 IN WITNESS WHEREOF, this Agreement has been duly executed by or on behalf of the parties hereto
as of the date first above written. 
  

			
	ONCOTHYREON INC.:
		
	By:	 	  

	Name:	 	
	Title:	 	
	
	EXECUTIVE:
	
	  

	Name:	 	
	
	Address:

 Exhibit A 

FORM OF GENERAL RELEASE OF ALL CLAIMS 

THIS GENERAL RELEASE OF ALL CLAIMS (this “General Release”), dated as of
[                    ], is made by and between
[                    ] (the “Executive”) and Oncothyreon Inc. (together with its successors and assigns, the
“Company”). 
 WHEREAS, the Company and Executive are parties to that certain Employment Agreement, dated as of May
    , 2016 (the “Employment Agreement”); 
 WHEREAS, Executive’s employment with the Company has
been terminated and Executive is entitled to receive severance and other benefits, as set forth in Section 5 of the Employment Agreement subject to the execution of this General Release; 

WHEREAS, in consideration for Executive’s signing of this General Release, the Company will provide Executive with such severance and
benefits pursuant to the Employment Agreement; and 
 WHEREAS, except as otherwise expressly set forth herein, the parties hereto intend
that this General Release shall effect a full satisfaction and release of the obligations described herein owed to Executive by the Company. 

NOW, THEREFORE, in consideration of the premises and other good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the parties hereto hereby covenant and agree as follows: 
 1. Executive, for himself, Executive’s spouse, heirs, administrators,
children, representatives, executors, successors, assigns, and all other individuals and entities claiming through Executive, if any (collectively, the “Executive Releasers”), does hereby release, waive, and forever discharge the
Company and its affiliates and each of its and their respective agents, subsidiaries, parents, affiliates, related organizations, employees, officers, directors, attorneys, successors, and assigns in their capacities as such (collectively, the
“Employer Releasees”) from, and does fully waive any obligations of Employer Releasees to Executive Releasers for, any and all liability, actions, charges, causes of action, demands, damages, or claims for relief, remuneration, sums
of money, accounts or expenses (including attorneys’ fees and costs) of any kind whatsoever, whether known or unknown or contingent or absolute, which heretofore has been or which hereafter may be suffered or sustained, directly or indirectly,
by Executive Releasers in consequence of, arising out of, or in any way relating to: (a) Executive’s employment with the Company; (b) the termination of Executive’s employment with the Company; (c) the Employment Agreement; or (d) any
events occurring on or prior to the date of this General Release. The foregoing release and discharge, waiver and covenant not to sue includes, but is not limited to, all waivable claims and any obligations or causes of action arising from such
claims, under common law including wrongful or retaliatory discharge, breach of contract (including but not limited to any claims under the Employment Agreement other than claims for unpaid severance benefits, bonus or Salary earned thereunder) and
any action arising in tort including libel, slander, defamation or intentional infliction of emotional distress, and claims under any federal, state or local statute including the Age Discrimination in Employment Act (“ADEA”), Title
VII of the Civil Rights Act of 1964, the Civil Rights Act of 1866 and 1871 (42 U.S.C. § 1981), the National Labor Relations Act, the Fair Labor Standards Act, the Employee Retirement Income Security Act, the Americans with Disabilities Act of
1990, the Rehabilitation Act of 1973, or the discrimination or employment laws of any state or municipality, and/or any claims under any express or implied contract which Executive Releasers may claim existed with Employer Releasees. This also
includes a release of any claims for wrongful discharge and all claims for alleged physical or personal 

 
injury, emotional distress relating to or arising out of Executive’s employment with the Company or any of its subsidiaries or affiliates or the termination of that employment; and any
claims under the WARN Act or any similar law, which requires, among other things, that advance notice be given of certain work force reductions. Notwithstanding anything contained in this Section 1 above to the contrary, nothing contained in
herein shall constitute a release by any Executive Releaser of any of his, her or its rights or remedies available to him, her or it, at law or in equity, related to, on account of, in connection with or in any way pertaining to the enforcement of:
(i) any rights to the receipt of employee benefits which vested on or prior to the date of this General Release; (ii) the right to receive severance and other benefits under the Employment Agreement; (iii) any equity rights; or (iv) this General
Release or any of its terms or conditions. 
 2. Excluded from this General Release and waiver are any claims which cannot be waived by applicable law,
including but not limited to the right to participate in an investigation conducted by certain government agencies. Executive does, however, waive Executive’s right to any monetary recovery should any government agency (such as the Equal
Employment Opportunity Commission) pursue any claims on Executive’s behalf. Executive represents and warrants that Executive has not filed any complaint, charge, or lawsuit against the Employer Releasees with any government agency or any court.

 3. Executive agrees never to seek personal recovery from any Employer Releasee in any forum for any claim covered by the above waiver and release
language, except that Executive may bring a claim under the ADEA to challenge this General Release. If Executive violates this General Release by suing an Employer Releasee (excluding any claim by Executive under the ADEA or as otherwise set forth
in Section 1 hereof), then Executive shall be liable to the Employer Releasee so sued for such Employer Releasee’s reasonable attorneys’ fees and other litigation costs incurred in defending against such a suit. Nothing in this
General Release is intended to reflect any party’s belief that Executive’s waiver of claims under ADEA is invalid or unenforceable, it being the intent of the parties that such claims are waived. 

4. Executive agrees that neither this General Release, nor the furnishing of the consideration for this General Release, shall be deemed or construed at any
time to be an admission by the Employer Releasees of any improper or unlawful conduct. 
 5. Executive acknowledges and recites that he has: 

(a) executed this General Release knowingly and voluntarily; 

(b) had a reasonable opportunity to consider this General Release; 

(c) read and understands this General Release in its entirety; 

(d) been advised and directed orally and in writing (and this subparagraph (d) constitutes such written direction) to seek legal counsel and
any other advice Executive wishes with respect to the terms of this General Release before executing it; and 
 (e) relied solely on
Executive’s own judgment, belief and knowledge, and such advice as Executive may have received from Executive’s legal counsel. 
 6. Section 12 of
the Employment Agreement, which shall survive the expiration of the Employment Agreement for this purpose, shall apply to any dispute with regard to this release. 

  
 - 13 - 

 7. Executive acknowledges and agrees that (a) his execution of this General Release has not been forced by any
employee or agent of the Company, and Executive has had an opportunity to negotiate the terms of this General Release; and (b) he has been offered twenty-one (21) calendar days after receipt of this General Release to consider its terms before
executing it. Executive shall have seven (7) calendar days from the date he executes this General Release to revoke his or her waiver of any ADEA claims by providing written notice of the revocation to the Company, as provided in Section 10 of the
Employment Agreement. 
 8. Capitalized terms used but not defined in this General Release have the meanings ascribed to such terms in the Employment
Agreement. 
 9. This General Release may be executed by the parties in one or more counterparts, each of which shall be an original and all of which shall
together constitute one and the same instrument. Each counterpart may be delivered by facsimile transmission or e-mail (as a .pdf, .tif or similar un-editable attachment), which transmission shall be deemed delivery of an originally executed
counterpart hereof. 
 IN WITNESS WHEREOF, the parties hereto have executed this General Release as of the day and year first above written.

  

			
	ONCOTHYREON INC.:
		
	By:	 	  

	Name:	 	
	Title:	 	
	
	EXECUTIVE:
	
	  

	Name:	 	
	Address:

  
 - 14 - 

 Exhibit B 

EMPLOYEE CONFIDENTIALITY, INVENTION ASSIGNMENT AND NON-COMPETE AGREEMENT 

THIS EMPLOYEE CONFIDENTIALITY, INVENTION ASSIGNMENT AND NON-COMPETE AGREEMENT (“Agreement”) is made as of the date set forth
on the signature page below between Oncothyreon Inc. (the “Company”), and the person whose name is set forth on the signature page below as Employee (“Employee”). 

In consideration of Employee’s employment or continued employment by the Company, with the intention that this Agreement shall apply to
the entire period of Employee’s employment with the Company (including the period prior to the date of this Agreement), Employee hereby agrees as follows: 

1. CONFIDENTIAL INFORMATION DEFINED. “Confidential Information” means trade secrets, proprietary information and materials, and confidential
knowledge and information which includes, but is not limited to, matters of a technical nature (such as discoveries, ideas, concepts, designs, drawings, specifications, techniques, models, diagrams, test data, scientific methods and know-how, and
materials such as reagents, substances, chemical compounds, subcellular constituents, cell or cell lines, organisms and progeny, and mutants, derivatives or replications derived from or relating to any of the foregoing materials), and matters of a
business nature (such as the identity of customers and prospective customers, clinical and regulatory development plans and data, clinical trial data, the nature of work being done for or by or being discussed with third parties, suppliers, and
service providers, marketing techniques and materials, marketing and business development plans, pricing or pricing policies, financial information, plans for further development, and any other information not available to the public). 

“Confidential Information” shall not include information that Employee establishes by competent evidence: (a) was in Employee’s
possession or in the public domain before receipt from the Company, as evidenced by the then existing publication or other public dissemination of such information in written or other documentary form; (b) becomes available to the public through no
fault of Employee; or (c) is received in good faith by Employee from a third party who is known to Employee to be not subject to an obligation of confidentiality to the Company or any other party. 

2. NON-DISCLOSURE OF CONFIDENTIAL INFORMATION OF THE COMPANY. Employee acknowledges that, during the period of Employee’s employment with the
Company, Employee has had or will have access to Confidential Information of the Company. Therefore, Employee agrees that both during and after the period of Employee’s employment with the Company, Employee shall not, without the prior written
approval of the Company, directly or indirectly (a) reveal, report, publish, disclose or transfer any Confidential Information of the Company to any person or entity; or (b) use any Confidential Information of the Company for any purpose or for the
benefit of any person or entity, except in the good faith performance of Employee’s work for the Company or to comply with an order from any court of competent jurisdiction. If Employee is required by a judicial or administrative authority or
court having competent jurisdiction to disclosed Confidential Information (including Confidential Information of third parties), Employee shall notify the Company as soon as feasible, shall cooperate with the Company should the Company seek a
protective order or other relief limiting or conditioning such disclosure and shall provide only the minimum information required whether or not a protective order or other relief is in place. Except to the limited extent of such disclosure, all
information so disclosed shall, as to Employee, remain subject to the terms of this Agreement. 
 3. NON-DISCLOSURE OF CONFIDENTIAL INFORMATION OF
OTHERS. Employee acknowledges that, during the period of Employee’s employment with the Company, Employee may have 

 
had or will have access to Confidential Information of third parties who have given the Company the right to use such Confidential Information, subject to a non-disclosure agreement between the
Company and such third party. Therefore, Employee agrees that both during and after the period of Employee’s employment with the Company, Employee shall not, without the prior written approval of the Company, directly or indirectly (a) reveal,
report, publish, disclose or transfer any Confidential Information of such third parties to any person or entity; or (b) use any Confidential Information of such third parties for any purpose or for the benefit of any person or entity, except in the
good faith performance of Employee’s work for the Company or to comply with an order from any court of competent jurisdiction. 
 4. PROPERTY OF THE
COMPANY. Employee acknowledges and agrees that all Confidential Information of the Company and all reports, drawings, blueprints, materials, data, code, notes and other documents and records (other than Employee’s personal address book),
whether printed, typed, handwritten, videotaped, transmitted or transcribed on data files or on any other type of media, and whether or not labeled or identified as confidential or proprietary, made or compiled by Employee, or made available to
Employee, during the period of Employee employment with the Company (including the period prior to the date of this Agreement) concerning the Company’s Confidential Information are and shall remain the Company’s property and shall be
delivered to the Company within five (5) business days after the termination of such employment with the Company or at any earlier time on request of the Company. Employee shall not retain copies of such Confidential Information, documents and
records. 
 5. PROPRIETARY NOTICES. Employee shall not, and shall not permit any other person to, remove any proprietary or other legends or
restrictive notices contained in or included in any Confidential Information. 
 6. INVENTIONS. 

(a) Employee shall promptly, from time to time, fully inform and disclose to the Company in writing all inventions, copyrightable material,
designs, improvements and discoveries of any kind which Employee now has made, conceived or developed (including prior to the date of this Agreement), or which Employee may later make, conceive or develop, during the period of Employee’s
employment with the Company, which pertain to or relate to the Company’s business or any of the work or businesses carried on by the Company (“Inventions”). This covenant applies to all such Inventions, whether or not they are
eligible for patent, copyright, trademark, trade secret or other legal protection; and whether or not they are conceived and/or developed by Employee alone or with others; and whether or not they are conceived and/or developed during regular working
hours; and whether or not they are conceived and/or developed at the Company’s facility or not. 
 (b) Inventions shall not include (i)
any Invention made, conceived or developed by Employee prior to Employee’s employment with the Company; or (ii) any Invention for which no equipment, supplies, facilities, or trade secret information of the Company was used and which were
developed entirely on Employee’s own time unless (A) the Invention relates directly to the business of the Company or to the Company’s actual or demonstrably anticipated research or development; or (B) the Invention results from any work
performed by Employee for the Company. 
 (c) All Inventions shall be the sole and exclusive property of the Company, and shall be deemed
part of the Confidential Information of the Company for purposes of this Agreement, whether or not fixed in a tangible medium of expression. Employee hereby assigns all Employee’s rights in all Inventions and in all related patents, copyrights
and trademarks, trade secrets and other proprietary rights therein to the Company. Without limiting the foregoing, Employee agrees that any copyrightable material shall be deemed to be “works made for hire” and that the Company shall be
deemed the author of such works under the United States Copyright Act, provided that in the event and to the extent such works are determined not to constitute “works made for hire”, Employee hereby irrevocably assigns and
transfers to the Company all right (including, without limitation, moral rights), title and interest in such works. 

  
 - 16 - 

 (d) Employee shall assist and cooperate with the Company, both during and after the period of
Employee’s employment with the Company, at the Company’s sole expense, to allow the Company to obtain, maintain, defend, and enforce patent, copyright, trademark, trade secret and other legal protection for the Inventions. Employee shall
sign such truthful documents, and do such things necessary, to obtain such protection and to vest the Company with full and exclusive title in all Inventions against infringement by others. Employee hereby appoints the Secretary of the Company as
Employee’s attorney-in-fact to execute any truthful documents on Employee’s behalf for this purpose. 
 (e) Employee shall not be
entitled to any additional compensation for any and all Inventions made during the period of Employee’s employment with the Company. 
 7. COVENANT
NOT TO COMPETE. If Employee is, at any time during Employee’s period of employment with the Company, employed in the discovery or development areas of the Company in a non-clerical position, or at the Vice President level or higher of the
Company, then this Section 7 shall apply. Employee and the Company agree that the services rendered by Employee are unique and irreplaceable, and that competitive use and knowledge of any Confidential Information would substantially and irreparably
injure the Company’s business, prospects and good will. Employee and the Company also agree that the Company’s business as a biopharmaceutical company is global in nature due to the type of products developed and commercialized by such
companies and being developed by the Company. Therefore, Employee agrees that during the period of Employee’s employment with the Company and for a period of one (1) year thereafter, Employee shall not, directly or indirectly, through any other
person, firm, corporation or other entity (whether as an officer, director, employee, partner, consultant, holder of equity or debt investment, lender or in any other manner or capacity): 

(a) develop, sell, market, offer to sell products and/or services anywhere in the world that (i) target Her-2 for the treatment of cancers,
(ii) are Chk1 kinase inhibitors, or (iii) have the same or similar technological approach or technology platform (e.g., same receptors, same mechanism of action, etc.) and have the same potential indication(s) as any product being developed, offered
or sold by the Company on the date of the termination of Employee’s employment with the Company for any reason, provided that the foregoing shall not be violated by Employee’s activities with an entity where the portion of the competitive
business involved is less than fifteen percent (15%) of the total expenditures of the portion of the entity that is under Employee’s supervision; 

(b) solicit, induce, encourage or attempt to induce or encourage any employee or consultant of the Company to terminate his or her employment
or consulting relationship with the Company, or to breach any other obligation to the Company (other than advertising not specifically targeted at the Company’s employees and serving as a reference upon request); or 

(c) interfere with, disrupt, alter or attempt to disrupt or alter the relationship, contractual or otherwise, between the Company and any
consultant, contractor, customer, potential customer, or supplier of the Company. 
 Employee acknowledges that the foregoing geographic,
activity and time limitations contained in this Section 7 are reasonable and properly required for the adequate protection of the Company’s business. In the event that any such geographic, activity or time limitation is deemed to be
unreasonable by a court, Employee shall submit to the reduction of either said activity or time limitation to such activity or period as the court shall deem reasonable. In the event that Employee is in violation of the aforementioned restrictive
covenants, then the time limitation thereof shall be extended for a period of time equal to the pendency of such proceedings, including appeals. 

  
 - 17 - 

 Notwithstanding anything contained in this Agreement to the contrary, Employee may own, directly
or indirectly, solely as an investment, securities of any person or company having a class of securities publically traded, if Employee is not a controlling person of, or a member of a group which controls, such person or company and Employee does
not, directly or indirectly own more than one percent (1%) of any class of securities of such person or company. 
 8. DISCLOSURE OF THIS AGREEMENT.
Employee hereby authorizes the Company to notify others, including but not limited to customers of the Company and any of Employee’s future employers, of the terms of this Agreement and Employee’s responsibilities under this Agreement.

 9. SPECIFIC PERFORMANCE. Employee acknowledges that money damages alone would not adequately compensate the Company in the event of a breach or
threatened breach by Employee of this Agreement, and that, in addition to all other remedies available to the Company at law or in equity, the Company shall be entitled to injunctive relief for the enforcement of its rights and to an accounting of
profits made during the period of such breach. 
 10. NO RIGHTS GRANTED. Employee understands that nothing in this Agreement shall be deemed to
constitute, by implication or otherwise, the grant by the Company to Employee of any license or other right under any patent, patent application or other intellectual property right or interest belonging to the Company. 

11. SEVERABILITY. 
 (a) Each of the
covenants provided in this Agreement are separate and independent covenants. If any provision of this Agreement shall be determined to be invalid or unenforceable, the remainder of this Agreement shall not be affected thereby and any such invalid or
unenforceable provision shall be reformed so as to be valid and enforceable to the fullest extent permitted by law. 
 (b) It is not a
defense to the enforcement of any provision of this Agreement that the Company has breached or failed to perform any obligation or covenant hereunder or under any other agreement or understanding between Employee and the Company. 

12. GOVERNING LAW. This Agreement shall be governed by and construed in accordance with the laws of the State of Washington without regard to conflict
of law rules. All suits and claims shall be made only in state or federal courts located in Washington. 
 13. SUPERSEDES OTHER AGREEMENTS. This
Agreement contains the entire agreement of the parties with respect to subject matter hereof and supersedes all previous agreements and understandings between the parties with respect to its subject matter. 

14. AMENDMENTS. This Agreement may not be changed, modified, released, discharged, abandoned or otherwise terminated in whole or in part except by an
instrument in writing, agreed to and signed by the Employee and a duly authorized officer of the Company. 
 15. ASSIGNMENT. Except as otherwise
specifically provided herein, neither party shall assign or transfer this Agreement nor any rights hereunder without the consent of the other party, and any attempted or purported assignment without such consent shall be void; provided,
however, that any assignment or transfer pursuant to a merger or consolidation, or the sale or liquidation of all or 

  
 - 18 - 

 
substantially all of the business and assets of the Company shall be valid without Employee’s consent, so long as the assignee or transferee (a) is the successor to all or substantially all
of the business and assets of the Company; and (b) assumes the liabilities, obligations and duties of the Company, as contained in this Agreement, either contractually or as a matter of law. Employee’s consent shall not be required for any such
transaction. This Agreement shall otherwise bind and inure to the benefit of the parties hereto and their respective successors, assigns, heirs, legatees, devisees, executors, administrators and legal representatives. 

16. ACKNOWLEDGEMENTS. THE EMPLOYEE ACKNOWLEDGES THAT (i) THE EMPLOYEE HAS READ AND FULLY UNDERSTANDS THIS AGREEMENT; (ii) THE EMPLOYEE HAS BEEN GIVEN THE
OPPORTUNITY TO ASK QUESTIONS; (iii) THE EMPLOYEE HAS RECEIVED A COPY OF THIS AGREEMENT, THE ORIGINAL OF WHICH WILL BE RETAINED IN THE EMPLOYEE’S PERSONNEL FILE; AND (iv) THE EMPLOYEE’S OBLIGATIONS UNDER THIS AGREEMENT SURVIVE THE
TERMINATION OF THE EMPLOYEE’S EMPLOYMENT WITH THE COMPANY FOR ANY REASON. 
 IN WITNESS WHEREOF, the parties have executed
this Agreement as of the date set forth below. 
  

			
	ONCOTHYREON INC.
		
	By:	 	  

		
	Title:	 	
		
	EMPLOYEE:	 	  

		 	(Print Name)
		
		 	  

		 	(Signature Here)
		
	Date:	 	  

		
	Address:	 	  

  
 - 19 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00258-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00258-of-00352.parquet"}]]